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Although Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is now 
considered a facultative anaerobe, and bacilli isolated from sputum specimen possess 
morphologies identified from bacilli growing aerobically and under oxygen deprived conditions, 
most of the targets for the antituberculosis drugs are readily found on bacilli that are thriving 
aerobically. This raises questions on the efficiency of antituberculosis drugs on eradicating the 
pathogen from the host during treatment. In this study to determine whether the antituberculosis 
drugs that are used currently for the treatment of TB have similar effect of these different 
populations of this mycobacterium, we grew this organism under aerobic and oxygen deprived 
environments and then subjected them to the antimicrobial agents. The minimum inhibitory 
concentration (MICs) of these isolates against nine antituberculosis drugs were determined under 
aerobic conditions for the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
assay and under both aerobic and anaerobic conditions using the Microscopic Observation Drug 
Susceptibility (MODS) assays. In addition the bactericidal activities of isoniazid, rifampicin, 
kanamycin and ofloxacin were tested and compared amongst MDR isolates that were growing 
aerobically and anaerobically.  
There were some differences in the MICs determined by the MTT assay and the MODS assay for 
some isolates. For the susceptible isolates the MICs from the MTT assay were higher than the 
MICs from the MODS assay. The reverse was true for the drug resistant isolates. The reference 
strain H37Rv was resistant to some of the antimicrobial agents that were tested in this study. 
This was under both methods. However, MICs measured under anaerobic conditions with 
anaerobic bacilli did not yield viable results due to absence of growth as the bacilli are known to 
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replicate at a negligible rate under anaerobic conditions.  The bacilli in the inoculum were viable 
as following 40 days of anaerobic incubation but upon aerobic incubation of these cultures, 
growth was observed. And again with the bactericidal assays that were conducted on the 
multidrug resistant (MDR) isolates proved this. Rifampicin was the most potent antimicrobial 
agent against the anaerobic M. tuberculosis as susceptibility to this antimicrobial agent increased 
















Chapter 1: Introduction 
 
Mycobacterium tuberculosis is a facultative intracellular bacterial pathogen (van Crevel et al., 
2002), that is associated with the world’s number one infectious killer disease tuberculosis (TB) 
(Sherman et al., 2001; Sasseti et al., 2003 Rachman et al., 2006). One third of the world’s 
population is latently infected with TB and in 2014, 1.5 million deaths caused by this disease 
were reported (WHO, 2015).   
Tuberculosis is transmitted through aerosols produced during coughing, sneezing and talking by 
symptomatic individuals infected with M. tuberculosis. The aerosolised organisms can infect any 
exposed individual independent of whether they are already infected or not. Following infection, 
one of three possibilities may occur. Firstly the infected individual develops active TB 
immediately. Such people are usually immunocompromised (Gumbo et al., 2004). The second 
option is that the immune system fights off the pathogen, totally eradicating it. This accounts for 
only 10 % of all infected individuals (Ahmad, 2011). The third possibility is that of latent 
infection, which occurs when an individual is infected but the bacilli are neither killed nor cause 
symptomatic disease. The bacilli are contained in the infected individual and can persist for 
decades with no symptoms (Kana et al., 2008). This last possibility is the one that is the most 
problematic as it is hard to eradicate latent M. tuberculosis. The large group of latently infected 
persons serves as a reservoir for symptomatic infections in the future. When conditions are 
favourable for the microbe, it can resuscitate and gain back its ability of causing symptomatic 
infection (Gumbo et al., 2004; Koul et al., 2008) that is contagious.  
Although antimicrobials for the treatment of TB have been available since the middle of the 20th 
century, this disease still remains a major public health concern (Sasseti et al., 2003). This 
4 
 
situation has worsened over the years as drug resistant strains have emerged.  Although there are 
treatment protocols available for susceptible and resistant TB, which are applied globally (WHO, 
2004), the number of drugs to which M. tuberculosis is resistant has increased over time and this 
is still continuing. 
Treatment regimens for TB vary from 6 months for patients infected with a susceptible strain to 
2 years for those infected with an extensively drug resistant (XDR) strain. Therefore there is still 
a need for more effective drugs that will also provide shorter duration of treatment (Wayne and 
Hayes, 1996; Ahmad et al., 2006).The currently used anti-tuberculosis (anti-TB) drugs are not 
effective in eradicating latent M. tuberculosis. This is at least partly due to the lack of 
information on latent M. tuberculosis (Ashiru et al., 2012). And also a number of studies have 
reported that in sputum specimens of individuals suffering from TB, a mixed population of 
bacilli thriving aerobically, microaerophilically and anaerobically are present in a specimen 
collected from each patient. This may mean that aerobic and anaerobic bacilli exist inside the 
same host (Fattorini et al., 2013). Clearly, for the eradication of TB, the treatment regimen must 
include antibiotics that are able to kill all three subpopulations that are inhabiting the host.   
Our study aimed to grow M. tuberculosis clinical isolates of different drug susceptibilities to 
survive under anaerobiosis and thereafter determine their survival outcome after being exposed 
to antibiotics that are currently used for the treatment of TB. These results would then be 
compared to the outcomes with aerobically thriving bacilli. We also conducted a gene expression 
assay to validate that the bacilli that we were working with were indeed under anaerobiosis. 
Work that has been done on gene expression assays on M. tuberculosis have shown that some of 
this organisms’ genes are up regulated under anaerobic conditions while others are down 
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regulated (Saxena et al., 2008). More information on clinical isolates will be useful in the 
development of drugs that are active against both active and latent M. tuberculosis.  
Aim:  
To determine the minimum inhibitory concentration (MICs) of the 1st and 2nd line drugs for 
treatment of Mycobacterium tuberculosis under aerobic and anaerobic conditions. 
Objectives: 
1) To culture and grow M. tuberculosis anaerobically by means of standing broth cultures. 
2) To confirm that 18 M. tuberculosis isolates that were cultured using the standing culture 
method, did indeed survive anaerobically using the gene expression method. 
3)   To determine MICs of the 1st and 2nd line drugs aerobically and anaerobically.      
4) To compare differences between MICs of aerobically and anaerobically growing M. 
tuberculosis isolates (n=18). 
 




Tuberculosis is an airborne infectious disease that is caused by Mycobacterium tuberculosis. 
During transmission of this pathogen, it is inhaled and engulfed and ingested by dendritic cells, 
type II alveolar pneumocytes, adipocytes and by alveolar macrophages. This may then result in 
the infection of the host (Ashiru et al., 2012). If infection occurs, macrophages are activated. The 
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activated macrophages then destroy most M. tuberculosis cells while others are able to survive.  
A series of biological events occurs which include the production of chemokines by the infected 
macrophages, which leads to the recruitment and migration of immune cells which later develop 
into matured macrophages, lymphocytes and neutrophils. The newly recruited and developed 
macrophages engulf the small number of surviving M. tuberculosis. These new macrophages 
internalize M. tuberculosis cells without destroying them (van Crevel et al., 2002; Koul et al., 
2008).  
As M. tuberculosis is inside the macrophage, the fusion of the phagosome with the lysosome and 
other regulatory activities are inhibited. This helps the microbe to survive inside the macrophage 
and also protects it from the immune system (Kaufmann and Britton, 2008). This is followed by 
exponential growth of M. tuberculosis, until the macrophages are activated by T-cell mediated 
immunity (van Crevel et al., 2002). Upon this activation, which is accompanied by the 
emergence of unfavourable growth conditions, that include low pH; limited nutrition, toxic fatty 
acids and low oxygen levels which exist in the granulomas and necrotic tissues, M. tuberculosis 
stops replicating i.e. the bacilli enters a stationary phase (van Crevel et al., 2002; Aly et al., 
2006; Koul et al., 2008). The low oxygen level causes the bacilli to survive anaerobically 
(Wayne and Hayes, 1996). All of this is a gradual process. 
Growth of the bacilli is arrested when the host is immunocompetent; this means that the host will 
be latently infected with TB until they become immunocompromised. If the latently infected 
individual doesn’t become immunocompromised they will harbour the bacilli for decades, 
without any symptoms or spreading the disease (Wayne and Hayes, 1996). In human beings 
immunosuppression leads to conditions inside the host that permit persistence of replicating M. 
tuberculosis. With the HIV pandemic increasing the number of immunocompromised individuals 
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(Wang et al., 2011) as well as with one third of the world’s population being latently infected 
with M. tuberculosis (Kaufmann and Britton, 2008), the number of patients in which 
resuscitation of oxygen deprived M. tuberculosis occurs is increasing and has led to TB being the 
number one killer infectious disease in the world (Gumbo et al., 2004; Koul et al., 2008).  
Under anaerobiosis, M. tuberculosis undergoes several physiological changes during which they 
transform from vegetative state that metabolises and multiplies under aerobic conditions to non-
replicating bacilli which persist under low or oxygen depleted environment (Papadopoulou et al., 
2007; Parrish et al., 2009). The latter together with low redox potential is known to be a 
characteristic of the granuloma. Hence, M. tuberculosis has been classified as a facultative 
anaerobe (Ramcharandra and Sturm, 2010; Ashiru et al., 2012). The bacilli that is surviving 
under anaerobic conditions (in the granuloma or necrotic tissue), then shits to a different 
pathophysiological pathway. The bacillis’ overall behaviour changes, including its virulence and 
macrophage invasion capacity, which are higher than of the bacilli thriving aerobically (Ashiru et 
al., 2012). These behavioural and physiological changes aid the bacilli in becoming resistant or 
tolerant to the macrophages’ bactericidal mechanisms (Wayne and Hayes, 1996; Aly et al., 2006; 








2.2 Anti-tuberculosis Therapy 
 
The TB pandemic continues to be a conundrum despite the existence of the pathogen for 
centuries. The causative agent of TB is an obligate pathogen (Warner and Mizrahi, 2006). Even 
after more than 40 years of usage of vaccines and antibiotics against this disease (Böttger, 2011; 
Keshavjee and Farmer, 2012), TB continues to be one of the biggest killer infectious diseases 
globally (WHO, 2015).  
2.2.1 Association of tuberculosis with Human Immunodeficiency Virus 
 
Studies have shown that the TB pandemic is enhanced by the HIV epidemic and limited 
availability of effective TB treatment (Ducati et al., 2006; Keshavjee and Farmer, 2012). The 
HIV-TB co-infection is a lethal association as the two diseases have a mutualistic relationship as 
they enhance each other’s progress in the infected individual (Razafimahefa et al., 2005; 
Schlipköter and Flahault, 2010). It has been witnessed that HIV infected individuals have higher 
chances of acquiring TB (Asif, 2013). This maybe because HIV compromises the activity of the 
immune system of infected individuals (Ducati et al., 2006). The compromised immune system 
is a favourable, conducive environment for acquiring new infections as well as for resuscitation 
of the latent bacilli into a vegetative form which then causes active disease (Kana et al., 2008). It 
has also been noted that infection from M. tuberculosis can accelerate progression of HIV 
infection to AIDS (Ahmad, 2011), hence TB is the number one killer infectious disease in 
individuals infected with HIV (Schlipköter and Flahault, 2010). 
In the mid 1980s, an increase in the number of deaths caused by TB occurred mainly because of 
AIDS, poverty and inadequate medical care. This has continued over the years, despite the 
discovery and use of vaccines and various antibiotics over the past decades (Ducati et al., 2006). 
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2.2.2 Tuberculosis therapy and drug resistance 
 
 Another factor in fueling the TB pandemic has been the emergence of drug resistant strains. 
Drug resistant strains are believed to have developed as the result of failure to implement proper 
TB control programmes, poor management of TB cases and the long treatment duration (Hu et 
al., 1998; Parrish et al., 2009; Calver et al., 2010; Schlipköter and Flahault, 2010). The 
emergence of M. tuberculosis strains that are drug resistant and the pathogens success in being 
the dominating pathogen globally has necessitated an increased intensity in the search for new 
anti-TB drugs (McDonough et al., 1993; Ducati et al., 2006), as the currently used drugs are fast 
becoming irrelevant as this organism has become tolerant and resistant to them. Such strains are 
the multidrug resistant (MDR) and the XDR) strains.  MDR strains are resistant to at least 
rifampicin (RIF) and isoniazid (INH) while XDR strains are resistant to RIF, INH and 
fluoroquinolones and at least one second-line injectable drug (WHO, 2015). 
 
2.2.3 Current tuberculosis chemotherapy  
 
The current standard TB chemotherapy is a minimum of six months for infections with 
susceptible strains, while it is up to 20 months for infections with the MDR strains (WHO, 
2015). During this period multidrug therapy is applied to suppress emergence of drug resistance 
(Zhao and Drlica, 2001), to treat extra-and intra-cellular bacteria in the actively metabolising and 
in the semi-dormant state and to shorten the treatment duration (Wayne and Hayes, 1996; 
Böttger, 2011; Drusano et al., 2011).This method is favoured over monotherapy which gives rise 
to resistant strains (Keshavjee and Farmer, 2012). The primary advantage of treatment with 
multiple drugs is that if an individual is infected with two or more strains that have different drug 
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susceptibilities, chances are that these strains will be susceptible to two or more of the applied 
combination therapy drugs, in that way no strain will survive. This leaves little chance for 
survival of the mutant strains, hence no emergence of drug resistance.  
First line treatment of TB is divided into the intensive and the continuation phase. In the 
intensive phase four antibiotics are administered and are thought to kill the majority of the 
vegetative bacilli responsible for the clinical manifestation of the disease.  In the continuation 
phase, two antibiotics are employed to sterilize the tissue by eliminating the minimally 
metabolically active bacilli (Ducati et al., 2006). A minimum of six months treatment duration is 
necessary to totally eradicate the disease in the infected individual (Böttger, 2011), infected with 
a susceptible strain. If the patient is not compliant or doesn’t complete the treatment this may 
lead to selection of drug resistant mutants and treatment failure or relapse of active disease 
(Rustad et al., 2008). Drugs such as fluoroquinolones, macrolides, aminoglycosides and various 
other second line drugs are in use for treatment of MDR and latent M. tuberculosis infections, 
but these are less effective, more toxic and more expensive than most first line drugs (Ducati et 
al., 2006; Özkütük et al., 2008). There has been success with the above mentioned drugs, but 
drug resistance has emerged to these drugs as well (García-García et al., 2004). Despite the 
success of combination chemotherapy and new drugs on the market, development of drug 
resistance continues to be a problem as more drug resistant strains continue to emerge 
(Keshavjee and Farmer, 2012). This may be due to the fact that the currently used drugs have 
little effect on anaerobic bacilli; even the combination of the two most potent anti-TB drugs, i.e. 




2.2.4 Failure of the current anti-tuberculosis chemotherapy 
 
Emergence of drug resistance is not only caused by ineffectiveness of some of the drugs used, 
but also by failure of patients to comply with treatment which in turn is caused by the long 
treatment duration (Joshi, 2011). The lack of information on metabolism of M. tuberculosis 
especially its metabolism under anaerobic conditions has made this pathogen hard to eradicate. 
Targets of most of the currently used drugs are readily found on vegetative M. tuberculosis and 
therefore they may have minimal effect on bacilli that’s surviving under anaerobiosis as M. 
tuberculosis surviving anaerobically lacks the usual drug targets (Marttila et al., 1999; Miki et 
al., 2001; Ramcharandra and Sturm, 2010).  
During latency it is known that bacteria enter a state of no or minimal metabolic activity (Ducati 
et al., 2006) as a result of being inside the hosts’ bactericidal macrophages (Zhang and Yew, 
2009). This is a problem as M. tuberculosis does not only do this but it also enters a state of 
anaerobiosis once it is inside the hosts’ body if the hosts’ immune system is competent. In a 
study done by Garton et al., (2002), they discovered that bacilli isolated from sputum specimens 
were phenotypically different from bacilli that are cultured in the laboratory. They hypothesised 
that this may be due to the different environmental conditions that these two bacilli populations 
are thriving under. The structures described by Garton et al., in 2002 as lipid bodies on the bacilli 
seen in sputum specimens have been observed in bacilli that are surviving under anaerobiosis in 
macrophages (Peyron et al., 2008). The phenotypic similarity of the different bacilli populations 
present in the sputum samples and the bacilli grown in the laboratory at different oxygen 
gradient concentrations (Rustad et al., 2008), emphasising the need for more drugs that show 
dual activity against both aerobic and anaerobic bacilli.  
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The lack of knowledge on M. tuberculosis’ anaerobic pathophysiology has hampered the 
development of more drugs that are active against anaerobic bacilli. Most of the pathogenesis 
studies and the development of new anti-TB drugs are conducted using the aerobically grown 
cultures. These do not give a complete indication about M. tuberculosis’ adaptation ability and 
characteristics, hence scientific advancement in eradicating TB is slow (Rachman et al., 2006; 
Ashiru et al., 2012).  
 




Isoniazid (INH) is one of the first line drugs used for the treatment of TB (Özkütük et al., 2008) 
and is one of the two drugs considered to be the most powerful anti-TB drugs (WHO, 2015) and 
the backbone of anti-TB chemotherapy (Ducati et al., 2006). It is also one of the most affordable 
anti-TB drugs (Kelley et al., 1997). Isoniazid was first used for the treatment of TB in 1951 
(Böttger, 2011; Keshavjee and Farmer, 2012). 
 
Figure 2.2.5.1: Structure of Isoniazid  
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This nicotinamide analogue (Figure 2.2.5.1) is bactericidal and is mostly effective against 
vegetative bacilli (Ducati et al., 2006; Kolyva and Karakousis, 2012). Isoniazid targets mycolic 
acids biosynthesis (Hazbo´n et al., 2006) and nucleic acids biosynthesis (Timmins and Deretic, 
2006) by being activated by the KatG enzyme (catalase-peroxidase) produced by M. tuberculosis 
(Ducati et al., 2006).It is a pro-drug that is activated through oxidation in the intra-cellular 
environment of the bacilli. The resulting metabolites then inhibit the bacilli’s mycolipid 
synthesis which is essential for mycobacterial survival (Kolyva and Karakousis, 2012).  
Although INH has proven to be the most effective drug for the treatment of TB, it has also 
become the most affected drug in terms of drug resistance development (Kolyva and Karakousis, 
2012). The development of MDR and XDR strains as well as dormant bacilli are proof of this 
(Zhang and Yew, 2009; Filippini et al., 2010) as the latter are harder to eradicate due to their 
reduced susceptibility to the routinely used anti-TB drugs such as RIF and INH (Wayne and 
Hayes, 1996).  
Resistance to INH is a result of mutations in either katG, inhA, ahpC, kasA, ndh and/or oxyR 
genes (Silva et al., 2003; Ducati et al., 2006; Hazbo´n et al., 2006; Kolyva and Karakousis, 
2012), with the katG mutations being most frequent (Silva et al., 2003). The katG, inhA, ndh and 
ahpC genes encode enzymes, namely catalase peroxidise, putative mycolic acid synthesis 
enzyme, NADH dehydrogenase and alkyl hydroxiperoxidase respectively (Silva et al., 2003; 
Kolyva and Karakousis, 2012). Mutations in the inhA gene interrupt the synthesis of essential 
mycolic acids (Hazbo´n et al., 2006), while mutations in the ahpC gene cause an over expression 
of this gene (Kelley et al., 1997). A quarter of the clinical strains that have been confirmed as 
INH resistant, do not have mutations in any of the above mentioned known genes. This suggests 
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other mechanisms that may be responsible for this trait in these strains (Kolyva and Karakousis, 
2012).   
2.2.5.2 Rifampicin 
 
Rifampicin (RIF) (Figure 2.2.5.2) is a broad spectrum bactericidal antibiotic (Campbell et al., 
2001) and its spectrum includes M. tuberculosis (Campbell et al., 2001; Louw et al., 2011). This 
anti-TB drug belongs to the rifamycin group (Kolyva and Karakousis, 2012). Antibiotics from 
the rifamycin group have a lipophilic profile. This trait makes the diffusion of RIF across the 
membrane of the M. tuberculosis cell to be easy (Kolyva and Karakousis, 2012).  
 
 
Figure 2.2.5.2: Structure of Rifampicin 
After penetrating the mycobacterial cell envelope, the drug binds to DNA-dependant RNA 
polymerase, forming a drug-enzyme complex thereby inhibiting transcription of DNA to RNA 
hence protein synthesis is inhibited (Miki et al., 2001; Gumbo, 2010; Kolyva and Karakousis, 
2012; Asif, 2013). Because of these characteristics RIF has become one of the best drugs for the 
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treatment of TB and forms with INH the backbone for successful TB control programmes 
(Jayaram et al., 2003; Keshvjee and Farmer, 2012). RIF was first used as anti-TB drug in 1957 
(Keshvjee and Farmer, 2012). Its addition to the treatment regimen of TB shortened the 
treatment duration from 18 months to 9 months (Joshi, 2011; Kolyva and Karakousis, 2012). 
This concentration dependant drug is the most effective drug when it comes to killing anaerobic 
bacilli (Jayaram et al., 2003; Joshi, 2011). Although RIF has become one of the major drugs for 
the treatment of TB, its interaction with ARV drugs when used in HIV-TB co-infected 
individuals has limited the usage of this drug, as its concentration drops to sub-therapeutic levels 
when used together with ARVs (Diaz et al., 2003; Asif, 2013).  
Mono-resistance to RIF is not common, as most (90%) of the RIF resistant strains are also 
resistant to INH (Kolyva and Karakousis, 2012). Resistance to this drug occurs when there are 
mutations in the rpoB gene which encodes for the β subunit of the RNA polymerase (Campbell 
et al., 2001; Hwang et al., 2003; Louw et al., 2011; Kolyva and Karakousis, 2012). Mutations in 
the rpoB gene are the only known mechanism of resistance to this drug, as less than 5% of the 
known RIF’s resistant strains do not have mutations in the rpoB gene (Campbell et al., 2001; 




Ethambutol (EMB) (Figure 2.2.5.3) is a narrow spectrum (Chopra and Brennan, 1998; Jadaun et 
al., 2007) bacteriostatic anti-TB drug (Faugeraux et al., 2007; Salgado-Moran et al., 2013) and is 
one of the four drugs currently used for first line treatment of TB (WHO, 2015). This drug that 
has poor sterilizing activity, was first reported to have anti-TB activity in 1961 (Yendally and 
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Lee, 2008; Kolyva and Karakousis, 2012). Due to its moderate activity against the bacilli, it is 
used in combination with other anti-TB agents to supplement its activity (Yendapally and Lee, 
2008). It inhibits the synthesis of the mycobacterial cell wall by binding to the 
arabinosyltransferases, the enzymes that are responsible for the synthesis of arabinogalactan and 
lipoarabinomannan. These two compounds are essential components of the cell wall (Faugeroux 




Figure 2.2.5.3: Structure of Ethambutol 
Resistance to EMB is caused by point mutations in the embCAB operon, specifically in the 
EmbB subunit of the arabinosyltransferase (Kolyva and Karakousis, 2012; Salgado-Moran et al., 
2013). Once this mutation has occurred the activity of arabinosyltransferases is reduced, 









Aminoglycosides normally act in synergy with other antibiotics (Kotra et al., 2000), and bind to 
the 30S ribosomal subunit, which affects polypeptide synthesis resulting in the inhibition of 
translation during protein synthesis (Honroé and Cole, 1994; Chopra and Brennan, 1998; Zhang 
and Yew, 2009; Kolyva and Karakousis, 2012). Over the years there have been a number of 
reports on resistance to aminoglycosides (Kotra et al., 2000). 
Kanamycin (KAN) is an aminoglycoside that is used for the treatment of MDR-TB. This 
antibiotic inhibits protein synthesis. Resistance to KAN (Figure 2.2.5.4.1) is associated with 
mutations in the 1400 region of the rrs gene (Alangaden et al., 1998; Zhang and Yew, 2009) and 
mutations in the eis promoter region. Mutations in the eis promoter region cause an 
overexpression of aminoglycoside acetyltransferase which inactivates kanamycin (Zaunbrecher 
et al., 2009).  There is usually cross-resistance between this drug and amikacin which is also an 
aminoglycoside. This cross-resistance is more likely to be caused by mutations in the rrs gene 
rather than mutations in the eis promoter region as the aminoglycoside acetyltransferase enzyme 
inactivates KAN but not amikacin (Zaunbrecher et al., 2009).  There have been strains that are 
resistant to these two antibiotics but did not have any mutations in the above mentioned gene (rrs 
gene); this hints that there may be other mutation/s or mechanisms that account for resistance to 





Figure 2.2.5.4.1: Structure of Kanamycin 
 
Streptomycin (STR) (Figure 2.2.5.4.2), a broad spectrum antibiotic (Chopra and Brennan, 1998) 
was the first antibiotic to be used for TB chemotherapy (Honroé and Cole, 1994; Kolyva and 
Karakousis, 2012). It was discovered in the 1940s, with the first patient to use it in 1944 
(Keshavjee and Farmer, 2012).  
 
 
Figure 2.2.5.4.2: Structure of Streptomycin  
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M. tuberculosis strains with mutations in the rpsL, rrs, and gidB genes encoding the S12 protein, 
16S rRNA and 7-methyl-guanosine methyltransferase respectively have been found to be 
resistant to STR (Honroé and Cole, 1994; Meier et al., 1994; Chopra and Brennan, 1998; Zhang 
and Yew, 2009). Efflux pumps have also been cited as the other mechanism contributing 




Linezolid (LIN) (Figure 2.2.5.5) is a synthetic drug that belongs to the class of antibiotics called 
oxazolidinones (Vardakas et al., 2009; Long and Vester, 2012). It was the first drug from this 
group of antibiotics to be approved for clinical use (Kolyva and Karakousis, 2012). It is one of 
the latest additions in the market of antibiotics as it was first introduced in year 2000 (Long and 
Vester, 2012). It is used for treatment of serious infections that are caused by gram positive 




Figure 2.2.5.5: Structure of Linezolid 
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It inhibits protein synthesis by binding to the bacterial 23S rRNA of the 50S subunit during the 
formation of the 70S initiation complex (Vardakas et al., 2009; Long and Vester, 2012; Kolyva 
and Karakousis, 2012). Its use is limited due to its toxic effects; hence it is only used for a 
limited period of time in treatment regimens or resistant TB (Kolyva and Karakousis, 2012). Its 
use was first reported in 2003 by von der Lippe et al., (2006).  So far, resistance to this drug in 
M. tuberculosis is rare although it has been observed with other pathogens (Vardakas et al., 
2009). 
 
2.2.5.6 p-aminosalicylic acid 
 
The discovery of p-aminosalicylic acid (PAS) (Figure 2.2.5.6) was as early as the 1800s, and its 
antimycobacterial activity was recognized in 1946 (Chopra and Brennan, 1998). It was first 
prescribed for treatment of TB in 1948 (Kolyva and Karakousis, 2012). Despite the early 
discovery, its mechanism of action is still not well understood, but it is thought to inhibit the 
biosynthesis of folic acids and the uptake of iron (Chopra and Brennan, 1998; Kolyva and 
Karakousis, 2012). 
 
Figure 2.2.5.6: Structure of p-aminosalylic acid 
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Mutations in the thyA gene which encodes for an enzyme involved in the folate biosynthesis 
pathway have been identified in a third of M. tuberculosis strains that are resistant to this 




Ofloxacin (OFL) (Figure 2.2.5.7) is a broad spectrum bactericidal antibiotic that belongs to a 
group of antibacterial agents called the fluoroquinolones (Chopra and Brennan, 1998; Kolyva 
and Karakousis, 2012). Ofloxacin is a synthetic derivative of nalidixic acid (Chopra and 
Brennan; 1998) and is used as part of the second line treatment regimen for TB 
andrecommended by WHO for the treatment of MDR (Shandil et al., 2007). It kills bacteria by 
inhibiting the activities of DNA gyrase and DNA topoisomerase IV, thereby preventing DNA 
replication and its resolution and transcription (Chopra and Brennan, 1998; Piddock, 1998; 
Zhang and Yew, 2009). Since M. tuberculosis doesn't have DNA topoisomerase IV, DNA gyrase 
is ofloxacin’s only target in this organism (Kolyva and Karakousis, 2012).  
 
 
Figure 2.2.5.7: Structure of Ofloxacin 
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M. tuberculosis strains that have mutations in gyrA and gyrB which encode the A and B subunits 
of the DNA gyrase are resistant to this drug (Zhang and Yew, 2009; Kolyva and Karakousis, 
2012). There have been strains that are reported to be resistant to OFL, but do not have mutations 
in these two genes. This observation suggests that there are other genes or mechanisms that may 
be responsible for resistance to this drug that are yet to be elucidated (Kolyva and Karakousis, 




Capreomycin (CAP) (Figure 2.2.5.8) is a macrocyclic polypeptide that is isolated from 
Streptomyces capredus and is used in the second line regimen of treatment of TB (Zhang and 
Yew, 2009; Kolyva and Karakousis, 2012; Asif, 2013). Its spectrum is restricted to species of the 
genus Mycobacterium (Chopra and Brennan, 1998; Kolyva and Karakousis, 2012). 
 
Figure 2.2.5.8: Structure of Capreomycin 
Its mode of action lies with its ability to inhibit protein synthesis (Kolyva and Karakousis, 2012). 
A similar mode of action is exhibited by viomycin which is structurally related to CAP and also 
shares co-resistance with this anti-tuberculosis agent (Chopra and Brennan, 1998). Strains 
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resistant to CAP have been found to have mutations in the tlyA gene which encodes rRNA 
methyltransferase (Zhang and Yew, 2009) and the rrs gene which encodes 16S rRNA (Kolyva 
and Karakousis, 2012). It shares this with the aminoglycosides and therefore co-resistance with 
KAN and AMK is often found. 
 
2.2.6 The ‘Ideal’ anti-tuberculosis drug 
 
From the description of the above mentioned drugs it is clear that each of the anti-TB drugs has 
its specific mechanism for fighting the invading M. tuberculosis (Marttila et al., 1999; Miki et 
al., 2001) and that most of the currently used drugs have bactericidal activity mostly against 
replicating bacteria, which in turn makes them more effective in killing actively growing bacilli, 
while latent bacilli are tolerant to these drugs (Zhang et al., 2012). This, together with the 
growing emergence of strains resistant to a multitude of drugs enforces the growing need for new 
drugs that are active against both actively growing and latent bacilli (Koul et al., 2008).  
According to Koul et al., (2011), an ideal drug for the treatment of TB needs to be able to 
shorten the treatment duration, be active against drug resistant strains, and be taken less 
frequently and together with medications for other diseases without complications.  None of the 
drugs that are currently used as part of treatment of TB fit the above mentioned criterion 
completely.  Since most antimicrobial drugs interfere with metabolic pathways of the microbes, 
these drugs act on metabolically active bacilli and their activity is likely to be related to the level 
of metabolic activity. This is problematic as M. tuberculosis is known to enter into a phase which 
is non-replicating and shows minimal metabolic activity e.g. following macrophage invasion as 
this is its survival strategy against the hosts’ immune response. Although drugs such as RIF, 
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CAP and some other anti-TB drugs have shown some activity against dormant M. tuberculosis 
(Filippini et al., 2010), their activity is still not satisfactory.   
Studies have shown that the emergence of resistant strains is a result of the long treatment 
duration. The long treatment duration in turn is caused by the presence of dormant M. 
tuberculosis that take long to be eradicated as these bacilli are not killed rapidly enough during 
short treatment (Hu et al., 1998; Rustad et al., 2008; Parrish et al., 2009). During the long 
treatment duration it has been observed that cases of inadequate supply and taking of anti-TB 
drugs give the resistant mutants the opportunity to develop, thereby giving rise to drug resistant 
strains (Zhang and Yew, 2009; Singh et al., 2011). Dormant M. tuberculosis is able to return to 
active growth and cause active TB (Deb et al., 2009). This necessitates development of drugs 
that are active against the actively growing and the slow metabolising, dormant M. tuberculosis. 
The general assumption is that mutation will hardly or not at all occur during dormancy since 
such events occur only when replication takes place. However, recent evidence suggests 
otherwise.  Ford et al., (2011) showed that in the lungs of experimentally infected macacques, 
the mutation frequency was higher in animals with latent infection compared to active infection. 
In a not yet published study from our department it was shown that the mutation frequency in 
F15/LAM4/KZN and Beijing isolates was higher under anaerobic incubation as compared to 




Anaerobiosis is a biological metabolic pathway that a microbe shifts to in order to survive under 
anaerobic conditions (Drusano et al., 2010). This ability is reserved or seen in obligate and 
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facultative anaerobes. For facultative anaerobic microorganisms this process is usually 
accompanied by several morphological and physiological changes on the affected organism. 
These changes help the organism to adapt and survive in environmental conditions that are 
detrimental to aerobic organisms that do not have an ability of metabolizing anaerobically. 
Mycobacterium tuberculosis as a facultative anaerobe is no different in this behaviour. When M. 
tuberculosis is exposed to an anaerobic environment, it alters its metabolism to anaerobiosis, 
rather than sporulating as observed in some other bacteria (Drusano et al., 2010, Ramcharandra 
and Sturm, 2010).  
 
2.3.1 Environmental conditions inside the granuloma 
 
During pathogenesis as M. tuberculosis is engulfed by macrophages or is inside the granuloma it 
survives anaerobically. Under anaerobiosis, metabolism of M. tuberculosis is minimal, in such a 
way that it is assumed that it does not replicate or if it does, it replicates at a negligible rate 
(Parrish et al., 2009). The characteristic conditions of the granuloma include low redox potential, 
acidic environment, minimal oxygen concentration and minimal nutrients amongst others 
(Ahmad, 2010). These conditions have been mimicked in vitro by a number of methods. The 
Wayne model is one of the most widely used ones. The conditions in the granuloma that are 
thought to be beneficial for the successful survival of the M. tuberculosis cells inside the host are 
not conducive for the normal aerobic metabolism and growth of the bacterium (Nickel et al., 
2012). Mycobacterium tuberculosis therefore has to adapt to ensure survival in such an 
environment; it therefore enters a state of anaerobiosis, during which it stops replicating while 
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remaining viable, changing its gene expression pattern resulting in a different phenotype (Daniel 
et al., 2011).  
Although all the above mentioned conditions are responsible for the bacilli to enter the state of 
anaerobiosis inside the granuloma, oxygen limitation is the one characteristic that is thought to 
contribute the most to this metabolic change as the availability of nutrients is not limited during 
infection (Wayne and Lin, 1982). Upon availability of oxygen the dormant bacilli reverts back to 
thriving aerobically and multiplying (Voskuil et al., 2004; Nickel et al., 2012). The changes that 
are brought about by the harsh environmental conditions aid the bacterium to be tolerant to 
antibiotics that target aerobic biological pathways as these are either absent or minimal during 
anaerobiosis (Watanabe et al., 2011). This has been proven as much higher concentrations of 
anti-TB drugs are needed to eradicate latent bacilli than the concentrations used to eradicate 
vegetative bacilli, while some anti-TB drugs have shown better activity against latent bacilli than 
they have against multiplying bacilli (Filippini et al., 2010).     
 
2.3.2 The in vitro survival of Mycobacterium tuberculosis under anaerobiosis  
 
Achieving anaerobiosis in vitro by growing M. tuberculosis in liquid media in sealed tubes for 
certain duration is one of the established methods. There are several methods that are used to 
achieve this with M. tuberculosis, which include the Wayne model. In the Wayne model M. 
tuberculosis is inoculated in liquid media in tubes. The tubes are then sealed tightly to inhibit the 
introduction of oxygen into the tube. The tube is then incubated without agitation. During 
incubation access to oxygen is only limited to the oxygen which is already inside the tube, and 
over time as the oxygen and nutrients are utilized by the bacilli, these get depleted and the 
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environment in the tube becomes anaerobic and with limited nutrients (Rustad et al., 2008; 
Filippini et al., 2010; Watanabe et al., 2011). An accumulation of waste and acidification of 
media have also been observed (Rustad et al., 2008; Watanabe et al., 2011). As soon as the 
available oxygen becomes limited, the bacilli adopt low metabolic activity, with slow or no 
replication at all (Voskuil et al., 2004; Khan and Sarkar, 2006; Nickel et al., 2012). The bacilli 
then become dormant, triggering bacilli at the bottom of the tube to change their metabolism in 
order to survive under anaerobiosis (Wayne and Hayes, 1996). 
Once the bacilli are anaerobic, energy generation, RNA and protein synthesis decreases (Rustad 
et al., 2008; Drusano et al., 2010; Watanabe et al., 2011) and then a switch to anaerobic 
metabolism occurs (Voskuil et al., 2004). The bacilli also undergo structural changes such as the 
thickening of the cell wall and development of inclusion bodies (Anuchin et al., 2009).   
 
2.3.3 Survival and changes in gene expression in Mycobacterium tuberculosis inside the 
granuloma 
 
Bacilli surviving under anaerobiosis have thickened cell walls and there is an induction and 
repression of various genes (Zahrt, 2003). This is ensured by the ability of pathogens of being 
able to regulate a cascade of genes in response to the different antibacterial stresses encountered 
inside the host (Srivastava et al., 2008). Successful inhabitation of the granuloma by M. 
tuberculosis and persistence of the organism requires the bacilli to undergo changes 
morphologically (Christophe et al., 2009) and genetically (Li et al., 2002; Ahmad, 2010; Wang 
et al., 2011). All these changes require the bacilli to decrease and increase the expression of 
certain genes. Up regulation and down regulation of these genes depends on the function of the 
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gene. For M. tuberculosis the genes that are up-regulated are thought to aid the bacilli in 
remaining viable but not replicating or replicating at a slower rate (Saxena et al., 2008; Ahmad, 
2010; Shleeva et al., 2011).  
Mycobacterium tuberculosis isolated from sputum differs phenotypically to the bacilli that are 
propagated aerobically in vitro as a subpopulation of the bacilli isolated from it has 
triacylglycerol lipid bodies that are produced by a gene that is part of a regulon (Dos R regulon) 
which is associated with the anaerobic respiration (Garton et al., 2008). The Dos R regulon 
consists of a minimum of 48 genes (Voskuil et al., 2004; Leistikow et al., 2010; Kumar et al., 
2012). The activity of this regulon is induced in vitro when the bacilli are exposed to 
environmental conditions that are similar to those found in the granuloma such as low oxygen 
concentration (Nickel et al., 2012). This regulons’ mutants are not able to adapt in a hypoxic 
environment, showing the importance of this regulon for adaptation to anaerobic conditions 
(Fang et al., 2012).   
Studies have shown that when M. tuberculosis is exposed to different environmental conditions 
that are all thought to be encountered by the bacilli in the granuloma, these bacilli gave different 
gene expression profiles (Figure 2.3.3) (Deb et al., 2009). This indicates that environmental 
conditions that are encountered by the bacilli have an influence on expression of the genes by the 
bacilli. This in turn indicates that bacilli inhabiting different habitats may have different drug 




Figure 2.3.3: Expression of M. tuberculosis genes as the bacilli is surviving and adapting under 











Chapter 3: Methodology 
3.1 Preparation of antimicrobial dilution series 
 
Nine different anti-tuberculosis agents were used. For each of these, stock solutions were 
prepared in triplicate. For each drug an appropriate solvent was chosen as shown in table 3.1. 
The amount of each drug depended on the range of dilutions to be tested and the antimicrobial 
effect of the solvent. The drug solutions were sterilized through a 0.22 µm polyethersulfone 
membrane filter (Millipore, United Kingdom), except for rifampicin as for this compound 
methanol was used as a solvent. This alcohol is known to damage the filter. At the concentration 
used, methanol acts as a sterilising disinfectant. The stock solutions were stored in cryovials at -
20ºC in aliquots of 500 µl.  
 
To prepare the dilution series to be tested, the antibiotic stock solutions were thawed at room 
temperature (+ 25oC). Of each of the drug solutions, 0.5 ml was added to 4.5 ml of  OADC 
supplemented Middlebrook 7H9 broth (BD, Difco Laboratories, USA) (Based on the media that 
was used for the assay conducted). From this two-fold serial dilutions were prepared in a tissue 
culture plate with the appropriate number of the wells for each test. Each well contained twice 
the final concentration for each drug as shown in table 3.1. The test dilution series for each drug 
were determined based on published minimal inhibitory concentrations (MIC) of susceptible 
Mycobacterium tuberculosis (Table 3.1). This included two dilutions below and eight dilutions 





Table 3.1: Stock solutions and test range of the anti-tuberculosis agents 







of susceptible     
M. 
tuberculosis 
Isoniazid Distilled water 1280 64 – 0.0625 0.25 
Rifampicin Methanol:   
distilled water 
(30%)  
1280 64 – 0.0625 0.01 
Streptomycin Distilled water 2560 128 – 0.125 0.5 
Kanamycin Distilled water 20480 1024 – 1 4 
Ofloxacin 6.7% acetic 
acid: distilled 
water (1:1) 
5120 256 – 0.25 1 
Capreomycin Distilled water 20480 1024 – 1 4 
Para-aminosylic 
acid 
Distilled water 2560 128 – 0.125 0.5 
Linezolid Distilled water 2560 128 – 0.125 0.5 
Ethambutol Distilled water 20480 1024 – 1 4 
 
3.2 Preparation of Inoculum 
 
Eighteen clinical M. tuberculosis isolates from patients admitted to the Church of Scotland 
Hospital in Tugela Ferry, province of KwaZulu-Natal were used for this study. All isolates had 
been formerly fingerprinted by means of IS6110 RFLP and their resistance profile was 
determined with 1% proportional method on Middlebrook 7H10 agar. The genotypes and 
resistance profiles of these isolates are shown in table 3.2. Reference strain M. tuberculosis 
H37Rv ATCC 27294 was included as a control. All organisms were inoculated into 
supplemented Middlebrook 7H9 (BD, Difco Laboratories, USA) broth (see appendix A.1.1). 
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These broth cultures were incubated aerobically in an incubator with a horizontally rotating plate 
(shaker-incubator) at 37⁰C until the log phase was reached, defined as an OD600nm reading of 0.8 
- 1. To prepare cultures with single colonies two to three drops from these cultures were 
inoculated with a Pasteur pipette onto OADC supplemented Middlebrook 7H11 (BD, Difco 
Laboratories, USA) (see appendix A.1.4). The plates contained 200.000 units/L of Polymixin B 
(Sigma-Aldrich, USA); 20 mg/L of Amphotericin B (Sigma-Aldrich, USA); 100 mg/L of 
Carbenicilin (Sigma-Aldrich, USA) and 20 mg/L of Trimethoprim (Sigma-Aldrich, USA) 
(PACT) to avoid contamination. The culture was spread using a four way streak technique. The 
plates were sealed in gas permeable plastic bags and incubated aerobically at 37ºC in 5% CO2 for 
3 weeks. One single colony of each isolate was picked and inoculated in fresh OADC 
supplemented Middlebrook 7H9 (BD, Difco Laboratories, USA) (see appendix A.1.1) broth 
which was incubated aerobically in the shaker-incubator at 37ºC until visual turbidity was 
observed. Two to three drops of each broth culture were spread onto two OADC and PACT 
supplemented Middlebrook 7H11 (BD, Difco Laboratories, USA) plates to get a lawn of M. 
tuberculosis colonies. These plates were sealed in gas permeable plastic bags and incubated 
aerobically at 37ºC in 5% CO2 for 3 weeks, after which the culture was harvested and stored in 1 
ml aliquots at -80ºC in storage media consisting of protease peptone (BD, Difco Laboratories, 







Table 3.2: Genotypes and drug susceptibilities of the isolates used in the study 
 
Strain Genotype Classification* 
H37Rv Reference Strain SUS 
TF1582 Beijing SUS 
TF1413 Beijing SUS 
TF832 F11 variant SUS 
TF1538 Unique SUS 
TF1001 Unique SUS 
TF2034 Unique MDR 
MODS682 Unique MDR 
TF36480 F28 MDR 
TF2889 F28 MDR 
TF3203 F28 MDR 
MODS11 F15/LAM4/KZN MDR 
TF3228 F15/LAM4/KZN XDR 
MODS370 F15/LAM4/KZN XDR 
TF1762 F15/LAM4/KZN XDR 
TF1497 F15/LAM4/KZN XDR 
TF80164 F15/LAM4/KZN XDR 
TF3334 F15/LAM4/KZN XDR 
TF3229 F15/LAM4/KZN XDR 




To prepare the inoculum for MIC determination, stored cultures were thawed and a 100 µl 
volume was inoculated into 10 ml of OADC supplemented Middlebrook 7H9 broth (see 
appendix A.1.2). This culture was incubated for approximately two weeks at 37ºC in a shaker-
incubator until an optical density of 0.8 – 1.0 at OD600nm was obtained compatible with the log 
phase of growth.   
Oxygen deprived M. tuberculosis cultures were prepared according to Ramchandra and Sturm, 
(2010). A 2 ml volume of log phase culture was inoculated into 8ml of OADC supplemented 
Middlebrook 7H9 (BD, Difco Laboratories, USA) broth (see appendix A.1.2) in a 15 ml culture 
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tube (Sterilin Limited, Cambridge, UK). The tubes were tightly closed with a screw cap and 
sealed with parafilm. The cultures were incubated undisturbed for a minimum of two months at 
37ºC. 
To confirm the presence of Mycobacteria and the absence of contaminants the Ziehl-Neelsen 
Staining Method was applied. Smears were made on microscopy slides after each incubation 
step.  The smears were heat fixed on a hot plate for 2 hours and stained. The slide was then air 
dried at room temperature (± 25ºC) and viewed at 1000X magnification using a Nikon bright 
light microscope. 
 
3.3 Determination of the Minimum Inhibitory Concentrations of aerobic of M. tuberculosis 
 
Bacterial cultures that had been grown aerobically in OADC supplemented Middlebrook 7H9 
broth (see appendix A.1.2) were sonicated once at 15 Hz for 10 seconds, and the OD was 
measured at 600nm. Cultures with an OD of 0.7 to 1.4, containing approximately 108 colony 
forming units (cfu) per ml were used for the preparation of the inoculum to be used for the 
experiment. This suspension was diluted in supplemented Middlebrook 7H9 broth (see appendix 
A.1.2) to a concentration of 103cfu/ml and a volume equal to that of the antibiotic solution was 






3.3.1 (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) Assay 
 
A 96-well flat bottom microtitre plate was used for the (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) (MTT) assay. The assay was done three times for each drug per 
isolate. Two hundred microlitres of sterile triple distilled water was added to all the wells on the 
edge of the plate. Fifty microlitres of OADC supplemented Middlebrook 7H9 broth (see 
appendix A.1.2) was added to columns 3-11 from rows B-G and two fold serial dilutions of the 
drug to be tested were made in these rows, discarding 50 µl from the well with the lowest 
concentration. An equal volume of the inoculum was added to all the wells except the ones with 
water and the control wells. Experimental controls were as follows: broth only, drug only, 
culture only and MTT solution only (added on the day the MTT solution was added onto the rest 
of the place).  The plates were sealed in gas permeable plastic bags and incubated at 37ºC 
aerobically for 7 days for susceptible strains and H37Rv; while drug resistant strains were 
incubated for 14 days. After the incubation period, 7.5 µl of MTT (Sigma-Aldrich, USA) 
solution (5 mg/ml) was added to each experimental well. The plates were sealed again in gas 
permeable bags and incubated overnight at 37ºC aerobically. After overnight incubation, 25 µl of 
Sodium Dodecyl Sulphate (Sigma-Aldrich, USA)-Dimethylformamide (Sigma-Aldrich, USA) 
(SDS-DMF) solution [which was 20% SDS and 50% aqueous DMF (1:1 v/v)] was added to all 
wells. This was followed by another overnight incubation period at 37⁰C, aerobically in a sealed 
gas permeable plastic bag and colour change from yellow to purple, indicating growth, was 
noted. The minimum inhibitory concentration (MIC) was read as the lowest concentration that 




3.3.2 Microscopic Observation Drug Susceptibility Assay: Aerobic  
 
A 24–well flat bottom tissue culture plate was used for the Microscopic Observation Drug 
Susceptibility (MODS) assay. The assay was done three times for each drug per isolate. Five 
hundred microlitres of supplemented Middlebrook 7H9 broth (see appendix A.1.3) was added to 
all wells except wells A1 and C1. Onto these two wells 500 µl of the drug working solution was 
added and two-fold serial dilutions were made in each row starting from wells A2 and C2, 
discarding 500 µl from the well with the lowest concentration. Following this, 500 µl of the 
inoculum was added to all the wells except the controls. This resulted in final drug 
concentrations as summarised in table 3.1. Experimental controls were as follows: broth only, 
drug only and culture only.  The plates were sealed in gas permeable plastic bags and incubated 
at 37ºC aerobically for 14 days. After 14 days of incubation the contents of the wells were 
viewed under the Olympus CKX 41 inverted microscope (100X magnification). The MIC was 
interpreted as the lowest concentration that had no growth of M. tuberculosis as determined by 
the visualisation of whorls of bacteria due to M. tuberculosis typical cording. 
 
3.3.3 Microscopic Observation Drug Susceptibility Assay: Anaerobic 
 
For the anaerobic MODS assay, a similar procedure was followed except that all the work as 
well as the incubation (37ºC) was done in a Forma Scientific anaerobic chamber. Four isolates 
(TF1538; TF3203; TF3334 and TF3229) and H37Rv were chosen for the determination of the 
MICs under anaerobiosis.  
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Two different experiments were performed. In the first experiment, the MODS assay was done 
as described above using the cultures grown under oxygen deprivation (section 3.2).  
In the second experiment, six isolates (TF1538; TF1001; TF3203; TF3228; TF3229; TF3334) 
and H37Rv were cultured aerobically in OADC supplemented Middlebrook 7H9 broth (see 
appendix A.1.3) followed by MIC determination under anaerobic conditions. When the log phase 
of growth was reached, the MODS assay was performed as describe above with an inoculum 
containing 103cfu/ml. Isolates (TF1538 & TF1001) were tested for susceptibility to only INH 
and RIF; isolates (TF3203 & TF3228) to KAN and OFL and isolates (TF3229 & TF3334) to 
PAS and LIN and susceptibility of H37Rv was tested against the all six anti-TB drugs. The gas-
mix used in the anaerobic chamber was as follows: 5% of carbon dioxide, 10% hydrogen and 
85% nitrogen. The actual incubation gas mix had an undetermined lower hydrogen contents 
since this is converted to water during the removal of oxygen. To check culture viability, 5 µl of 
culture from the inoculum dilutions containing 1 ×103, 1 x 104 and 1 x 105 bacteria / ml was 
spread onto a 65 mm Middlebrook 7H11 agar plate. The plates were incubated aerobically in 
sealed gas permeable plastic bags at 37ºC in 5% CO2 for 3 weeks, after which the number of 
colonies on the plate were counted.  
 
3.3.4 Killing Experiments 
 
Following the analysis of the results from the MODS Assay, five MDR isolates were chosen for 
the time kill experiments with INH, RIF, KAN and OFL. If anaerobic conditions would increase 
the susceptibility to drugs, the MDR isolates should show kill at lower dilutions with INH and 
RIF. If the anaerobic conditions would make the organisms more drug tolerant, the opposite 
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would be observed with KAN and OFL. The test was done at different concentrations for each 
drug, for each isolate, as determined by the MIC obtained in the aerobic MODS assay. The assay 
was done three times for each drug per isolate under aerobic conditions while under anaerobic 
conditions the assay was done in duplicates for each drug per isolate. These concentrations were 
0.25X MIC, 1X MIC and 4X MIC. The concentrations for each drug per isolate are shown in 
table 3.3.  
Table 3.3: Drug concentrations used for the killing experiments for each isolate 
Isolates INH RIF OFL KAN 
TF2034 2 8 32 16 >64 256 0.125 0.5 2 0.5 2 8 
MODS682 8 32 128 16 >64 256 0.25 1 4 8 32 128 
TF36480 4 16 64 16 >64 256 1 4 16 256 >1024 4096 
TF2889 2 8 32 16 >64 256 0.125 0.5 2 2 8 32 
MODS11 16 64 256 2 8 32 0.25 1 4 0.5 2 8 
 
 
A suspension of 100µl M. tuberculosis stock culture was inoculated into 10 ml of OADC 
supplemented Middlebrook 7H9 broth (see appendix A.1.2). The suspension was incubated at 
37ºC in a shaker-incubator, until the culture reached the log phase of growth (see section 3.2). 
Upon reaching this phase, 1ml of the culture was inoculated into 9 ml OADC supplemented 
Middlebrook 7H9 broth (see appendix A.1.2) and was placed back in the same incubator under 
the same conditions. Another 1ml of the inoculum was inoculated into 9 ml OADC 
supplemented Middlebrook 7H9 broth (see appendix A.1.2) in a 15 ml culture tube (Sterilin 
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Limited, London, UK). The conditions for incubation were similar to section 3.2, with an 
incubation period of4 weeks.  
Once the aerobic cultures were in the log phase and following 4 weeks of incubation for the 
anaerobic cultures the following procedure was done for both experiments: 
All the anaerobic work was done inside the anaerobic chamber, while the aerobic work was done 
in the Biosafety Level 2 Cabinet. Briefly, 3 ml of each culture was inoculated into 42ml of 
OADC supplemented Middlebrook 7H9 broth (see appendix A.1.2). This suspension was divided 
into aliquots of 4.5 ml in 30 ml white capped tubes (Sterilin Limited, London, UK) for aerobic 
cultures and in 15 ml white capped tubes (Sterilin Limited, London, UK) for the anaerobic 
cultures. The drug working solutions (see section 3.1) with the desired concentrations (Table 3.3) 
were added to these aliquots. All the drug dilutions were done in triplicates. The aerobic cultures 
were incubated at 37ºC, in an incubator with a shaker-incubator for a week. The anaerobic 
cultures were incubated at 37ºC in the anaerobic chamber for a week as well. At day 0, 2 days 
and 7 days, 100 µl each antibiotic-bacterial isolate combination was transferred into a 1.5 ml 
microcentrifuge tube (Eppendorf, Germany) with 900 µl of phosphate buffer saline (PBS). The 
contents of the tubes were vortexed, followed by centrifugation at 12128 xg for 10 minutes. The 
supernatant was decanted, and the pellet was resuspended in 100 µl PBS, which was then 
vortexed and spread onto a 65 mm Middlebrook 7H11 agar (see appendix A.1.4) plate. The 
plates were dried for 30 minutes and then incubated aerobically for 3 weeks in 5% CO2 at 37ºC. 
One plate was inoculated for each dilution. Following aerobic incubation of the plates at 37ºC for 
3 weeks, the plates were checked and the percentage of growth was estimated in comparison 
with the growth on day 0 for each antibiotic-bacterial isolate combination.  
40 
 
N.B.: All the anaerobic work was done in the anaerobic chamber (as illustrated in section 3.2) 
except for the subculturing and the incubation of the Middlebrook 7H11 plates (see appendix 
A.1.4).     
Bacteriodes fragilis ATCC 25282 and Propionibacterium acnes ATCC 11827 were inoculated 
onto blood agar plates and incubated for 5 days aerobically and anaerobically, while a clinical 
isolate of Pseudomonas aeroginosa was inoculated onto nutrient agar aerobically and 
anaerobically. The plates were incubated overnight. These three organisms were used as 
biological controls as B. fragilis is a strict anaerobe and its growth in the anaerobic chamber 
indicated the presence of anaerobic conditions, whereas P. acnes as facultative anaerobe grew at 
a slower rate when it was incubated in the anaerobic chamber compared to when it was incubated 
aerobically. P. aeroginosa is a strict aerobe. No growth under anaerobic conditions confirms 
oxygen depletion inside the chamber while its growth aerobically confirmed viability of the test 
isolate. Methylene blue indicator strips were also used to confirm the absence of oxygen in the 
chamber. All controls confirmed anaerobiosis inside the chamber during the full operational 
period. 
 
3.4 Gene Expression 
 
3.4.1 RNA Extraction 
 
RNA was extracted from aerobically incubated as well as oxygen deprived cultures (refer to 
section 3.2) using the Trisure Nucleic Acid extraction protocol. The RNA was extracted from 
aerobically incubated cultures once the cultures were at the log phase growth, while from the 
41 
 
oxygen deprived cultures the RNA was extracted after 12 months of incubation, except for 
isolate TF3203 whose extraction was done after 10 months as it was inoculated and incubated 
later than the other isolates. Briefly, the culture was centrifuged at 3000xg at 4ºC for 30 minutes 
and the supernatant was discarded. The pellet was resuspended in 1ml of Trisure solution 
(Bioline, United Kingdom) and mixed by pipetting up and down. The mixture was then 
transferred into a 2 ml conical screw cap microtube with a cap that had an o-ring (Quality 
Scientific Products, USA) containing 0.1 mm diameter Zirconia/silica beads (BioSpec Products, 
Bartlesville, USA). The mixture was vortexed three times for 2 minutes with a 2 minutes break 
in between the vortexing steps during which the tubes were placed on ice. The Trisure and 
nucleic acid mixture was stored at -80ºC until the subsequent RNA extraction steps were carried 
out.  
The frozen Trisure mixture was thawed and centrifuged at 12000xg at 4ºC for 10 minutes.  The 
supernatant was transferred into a new tube and incubated at room temperature for 10 minutes. 
Cold chloroform (Sigma-Aldrich, USA) was then added and mixed vigorously by hand for 30 
seconds. The chloroform mixture was centrifuged at 12000xg at 4ºC for 10 minutes. The 
colourless upper aqueous phase was transferred into a new tube. Cold isopropanol (Sigma-
Aldrich, USA) was added and mixed with the aqueous phase by inverting the tube, followed by a 
rest phase of 15 minutes at room temperature. The liquid was centrifuged at 12000xg at 4ºC for 
10 minutes. The supernatant was carefully decanted without disturbing the RNA pellet. The 
pellet was then resuspended in 75% ethanol in Diethylpyrocarbonate (DEPC)-treated water 
(Sigma- Aldrich, USA) and agitated by hand. The solution was centrifuged at 7500xg for 5 
minutes at 4ºC. Following that the supernatant was discarded. The pellet was air-dried for 10 
minutes, followed by resuspension of the pellet in RNA Secure and incubation at 60ºC in a water 
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bath for 10 minutes. The RNA was quantified using the NanoDrop 2000c (Thermo Fischer 
Scientific, Inc., USA), with RNA Secure being used as a blank. This was then followed by the 
DNAase treatment according to the manufacturer’s instructions, using the RNA concentration of 
each sample as the reference for the amount of the reagents to be added.  Following the DNAse 
treatment the RNA was once again quantified using the NanoDrop 2000c with DEPC treated 
water as the blank. After quantification, the extracted RNA was stored at -80ºC until the 
subsequent cDNA synthesis step.  
 
3.4.2 Synthesis of Complimentary DNA (RT-PCR) 
 
For each sample 3 µl of loading dye was mixed with 10 µl of the RNA sample. This was loaded 
into the wells of a 2% agarose gel in 1X Tris-acetate-EDTA (TAE) buffer (Sigma-Aldrich, 
USA). Electrophoresis was performed at 100V for 1 hour. On completion of the run, the bands 
were viewed under UV light.  
Complementary DNA (cDNA) was synthesised using the ABI High capacity cDNA synthesis kit 
(Life Technologies, USA).The 2x RT master mix was prepared with volumes of ingredients 
shown in table 3.4.2. These were mixed and gently vortexed. Ten microlitres of 2x RT master 
mix was mixed with 10 ml of the prepared RNA. The mixture was vortexed, briefly centrifuged 
in a microcentrifuge and placed on ice until it was processed in the GeneAmp 9700 thermal 
cycler under the following conditions: 25ºC for 10 minutes followed by 37ºC for 120 minutes; 
which was followed by annealing for 5 seconds at 85ºC and finally at 4ºC indefinitely. Once the 
PCR reaction was complete the cDNA was stored at -20°C until further use.  
43 
 
Table 3.4.2: The quantities of the High-Capacity Reverse Transcription Kit reagents as 
used per reaction for the synthesis of cDNA synthesis 
Reagents Amount per reaction (µl) Concentration  
10x Buffer 2.0 - 
25x dNTP mix 0.8  100Mm 






RNase Inhibitor 1.0 20U/µl 
Nuclease free water 3.2 N/A 
RNA sample 10 ≤ 2µg  
Total 20 N/A 
 
3.4.3 Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) using the 
ABI 7500 system 
 
Applied Biosystems TaqMan® Gene Expression Assays (Life Technologies, USA) were used. 
Reaction volumes of 25 µl per well were used in a 96-well plate: 12.5 µl of TaqMan® Gene 
Expression PCR Master Mix (2✕) (Life Technologies, USA) was mixed with 1.25µl Assay Mix 
(20✕) (Life Technologies, USA) for each target (16SrRNA; menB; sdhA and fdxA); 2.5µl 
cDNA (diluted to a concentration of 50ng/µl) and 8.75µl of nuclease free water. The mixture was 
centrifuged briefly to remove air bubbles. The 96-well plate was placed into the ABI 7500 
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system (Life Technologies, USA) as per systems programme. Gene expression levels were 
normalized with 16SRNA levels of each sample tested. Table 3.4.3 displays the sequences of the 
primers and probes applied in the gene expression assays. The assay was done three times for 
each gene per isolate. 
 
Table 3.4.3: Sequences of the primers and probes of the genes used for qRT-PCR 









































Chapter 4: Results 
 
The critical concentrations proposed by WHO (WHO, 2009) for drug susceptibility testing 
(DST) in liquid media were used to evaluate the activity of the antimicrobial agents against the 
18 M. tuberculosis isolates used in this study. As there are no standard critical concentrations for 
DST against the antimicrobial agents used when performed in home-made Middlebrook 7H9 
broth the proposed critical concentrations for BACTEC460 and the MGIT960 were the closest 
concentrations that could be applied for the evaluation of the results from both the (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (MTT) and Microscopic Observation 
Drug Susceptibility (MODS) assays. These critical concentrations are shown in table 4. 
Table 4: Critical concentrations of anti-tuberculosis drugs as proposed by WHO for 
MGIT960 and BACTEC460                                                                             
Antibiotics Critical concentrations (mg/L) as proposed by WHO 
 MGIT960 BACTEC460 
Isoniazid 0.1 0.1 
 Rifampicin 1 2 
Ethambutol 5 2.5 
Streptomycin 1 2 
4-aminosalicylic acid - 2 
Ofloxacin 2 2 
Kanamycin - 4 
Capreomycin 2.5 1.25 
Linezolid 1 1 







4.1 Minimum Inhibitory Concentrations obtained with the MTT test 
 
When the WHO proposed (WHO, 2009) breakpoints (Table 4) for both the MGIT960 and 
BACTEC460 methods were used, H37Rv was found to be resistant to all drugs tested using the 
MTT assay except for ofloxacin (OFL), if the MGIT960 breakpoint for STR is used  (Table 4.1). 
Isolate TF1582 was the only one within the group of five susceptible isolates tested (Table 4.1) 
that was found to be susceptible to ethambutol (EMB) in the MTT assay if the breakpoint from 
the BACTEC460 was used.3 of the 5 of the susceptible isolates had an MIC of 0.25 mg/L for 
isoniazid (INH). Both H37Rv and TF1582 were susceptible to streptomycin (STR), while all the 
resistant isolates that were tested (TF36480 and TF3203, both MDR) had an MIC that was 
greater than 128 mg/L and XDR isolates TF1497 and TF80164 had an MIC of 16 mg/L. In the 
MTT assay, all the isolates were susceptible to OFL except for the XDR isolates (TF1497; 
TF80164 and TF3334) that had an MIC of 8 mg/L. 
 
Table 4.1: The MIC (mg/L) results of anti-tuberculosis agents of M. tuberculosis isolates 
under aerobic conditions as determined by the MTT Assay 
Strain Classification* INH EMB STR OFL 
H37Rv SUS 0.125 4 1 1 
TF1582 SUS N/T 2 0.5 ≤0.25 
TF1538 SUS 0.25 N/T N/T 0.5 
TF832 SUS 0.25 N/T N/T N/T 
TF1001 SUS 0.25 2 N/T 0.25 
TF36480 MDR N/T 32 >128 1 
TF3203 MDR N/T 16 >128 0.25 
TF1497 XDR N/T 32 16 8 
TF80164 XDR N/T N/T 16 8 
TF3334 XDR N/T 16 N/T 8 
*Classified according to resistance profile with 1% proportional method on Middlebrook 7H10 
agar 
N/T – Not Tested, as the experiments were being carried, it was established through literature 
that the MTT assay would not work under anaerobic conditions as M. tuberculosis has low 
metabolic activity.  
47 
 
4.2 MICs obtained with the MODS assay under aerobic conditions 
 
With the MODS assay a total of nine antimicrobial agents were tested. As illustrated in table 4.2, 
H37Rv showed unexpected resistance to several of the antimicrobial agents. TF1582 was the 
only isolate that was susceptible to all the anti-tuberculosis agents. The minimal inhibitory 
concentration for streptomycin (STR) for four of the six MDR isolates that were tested, was > 
128 mg/L since there was still growth at this concentration, being the highest concentration that 
was tested. All the MDR-F15/LAM4/KZN (KZN) isolates except for isolate MODS11 were 
resistant to ofloxacin (OFL). All the drug resistant isolates were resistant to kanamycin (KAN) 
except for KZN isolate MODS11 as well as TF2034, which was an isolate that was not from an 
identified genotype cluster. All the other KZN isolates had an MIC that was > 1024 mg/L. Isolate 
TF2034 was an exception in the group of the MDR isolates as it was the only one that had an 
MIC that was < 1 mg/L for capreomycin (CAP). All resistant isolates together with H37Rv had 
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4.3 Comparison between MTT and MODS assays 
 
Overall, the MICs that were determined by the MODS assay for the group of isolates classified 
as susceptible were either equal to or lower than the MICs determined by the MTT assay, with 
MICs for EMB being the exception (Table 4.3). For INH only the isolates grouped as susceptible 
and H37Rv were tested in the MTT assay. All these isolates’ MICs for INH were two folds 
higher compared to the MIC in the MODS assay, while the MIC for H37Rv was the same at 0.25 
mg/L. With this drug, four isolates showed identical results in both assays while for the other 
three antibiotics the MICs were higher in the MODS than in the MTT assay. The opposite was 
witnessed with the resistant isolates, with an exception of isolates TF36480 for EMB and 
TF80164 for STR (Table 4.3). Minimum inhibitory concentrations of STR from both the MTT 
and MODS assays were the same for isolates TF1582; TF36480 and TF3203, although with the 
latter two isolates that could change as 128 mg/L was the highest concentration that was tested 
for both assays. The minimum inhibitory concentrations in the MTT assay of this drug for isolate 
TF80164 and H37Rv were higher than the MICs in the MODS assay. TF1497 had an MIC of 32 
mg/L for STR in the MODS assay which was double the MIC obtained with the MTT assay. All 
the isolates whose susceptibility to OFL that were tested through both assays and showed similar 
susceptibility profiles, with the exception of TF36480 with a two-fold higher MIC of 1 mg/L in 
the MTT assay as compared to the MODS assay. All the XDR isolates (TF1497; TF80164 and 
TF3229) were resistant to OFL as they all had an MIC of 8 mg/L for this antimicrobial agent 
with both assays. The rest of the isolates that were tested for OFL were susceptible to this drug 
with MICs for isolates TF1582 and TF1001 and H37Rv remaining the same amongst the two 
assays. Based on the limited number of isolates tested with both assays, no trend was observed 
with respect to the level of the MIC between these assays. 
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Table 4.3: Comparison between MIC (mg/L) results of anti-tuberculosis agents of M. 
tuberculosis isolates under aerobic conditions as determined by the MODS and the MTT 
Assay 
Isolate Classification* INH EMB  STR  OFL 
H37Rv SUS 0.125 0.125 16 4  0.5 1  1 1 
TF1582 SUS ≤0.0625 N/T ≤1 2  0.5 0.5  ≤0.25 ≤0.25 
TF1538 SUS ≤0.0625 0.25 8 N/T  0.25 N/T  0.25 0.5 
TF832 SUS ≤0.0625 0.25 8 N/T  2 N/T  0.25 N/T 
TF1001 SUS ≤0.0625 0.25 8 2  0.5 N/T  0.25 0.25 
TF36480 MDR 16 N/T 16 32  >128 >128  4 1 
TF3203 MDR 16 N/T 64 16  >128 >128  1 0.25 
TF1497 XDR 32 N/T 32 32  32 16  8 8 
TF80164 XDR 64 N/T 64 N/T  2 16  8 8 
TF3334 XDR 64 N/T 32 16  4 N/T  8 8 
*Classified according to resistance profile with 1% proportional method on Middlebrook 7H10 
agar 
Red – MIC results with the MODS Assay 
Black – MIC results with the MTT Assay  
N / T – Not Tested, as the experiments were being carried, it was established through literature 
that the MTT assay would not work under anaerobic conditions as M. tuberculosis has low 
metabolic activity.  
 
 
4.4 MICs obtained with the MODS assay under anaerobic conditions  
 
We were unable to determine the MICs for any of the isolates under anaerobic conditions. After 
40 days of incubation of the inoculum of the 24 well tissue culture plates in the anaerobic 
chamber, there was no growth in the growth control. There was lack of growth in the MODS 
assay with both experimental methods used, i.e. using an inoculum that was grown under oxygen 
deprived conditions prior to conducting the MODS assay and using an inoculum that was grown 
aerobically prior to the MODS assay.  
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The biological controls B. fragilis and P. acnes grew in the anaerobic chamber while B. fragilis 
did not grow when it was incubated aerobically. Growth of P. Aeroginosa was the opposite of B. 
fragilis as this microorganism did not grow when it was incubated in the anaerobic chamber 
while it grew under aerobic incubation. P. acnes produced smaller colonies under aerobic 
conditions.  
 
4.5 The bactericidal effect of isoniazid, rifampicin, ofloxacin and kanamycin on MDR 
isolates under aerobic and anaerobic conditions / (Killing experiments) 
 
The results of the killing experiments are summarised in tables 4.5.1 and 4.5.2. Isoniazid had the 
lowest percentage kill, both aerobically and anaerobically. On day 2, there were no differences in 
percentage kill for INH when the experiments were conducted aerobically or anaerobically for 
all isolates except for TF2889 under aerobic conditions. At 0.25XMIC, this antibiotic was only 
able to kill bacteria from isolate TF2889 under anaerobic conditions on day 2 (Table 4.5.1). The 
rest of the isolates were not killed under both incubation conditions. At the MIC as determined 
by the MODS Assay, none of the isolates was killed. This was under both the conditions at 
which the incubation was carried out. Isolate TF2889 together with MODS11, were the only two 
isolates where kill was observed at day 7 with INH at a concentration of 4XMIC with a 
percentage kill of close to 100% each (Table 4.5.2). The killing was achieved under aerobic 
conditions only. There was no specific killing trend that was observed with this antimicrobial 
agent. 
Out of the four antibiotics that were used for the time-kill experiments RIF was the most 
successful one. This antimicrobial was the only one that was able to kill a substantial amount of 
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bacilli from all the isolates that were used, although this occurred at different concentrations and 
conditions. Under anaerobic conditions on day 2, RIF showed better activity towards isolates 
TF2034 and TF2889. No kill of these isolates was observed under aerobic conditions. RIF killed 
+100% of the inoculum of TF2889 at 0.25XMIC under anaerobic conditions (Table 4.5.1). At 
the concentration of 0.25X MIC, only one isolate (TF2889) was killed by RIF at day 2 under 
anaerobic conditions, while at the MIC concentration no kill was observed with any of the 
isolates. On day 2 under aerobic conditions RIF had no lethal effect on any of the isolates except 
MODS11. On day 7 this antibiotic was only able to kill isolates not belonging to an identified 
IS6110 lineage, namely MODS682 and TF2034 (Table 4.5.2) and this was under both aerobic 
and anaerobic conditions. The average percentage kill for these two isolates under both 
conditions was almost equivalent, with the percentage kill for TF2034 under anaerobic 
conditions being slightly greater, and the opposite was true for MODS682. Overall RIF was 
more lethal under anaerobic conditions, as by day 7 (Table 4.5.2) at a concentration of 4X MIC 4 
of the 5 isolates were killed.  At day 7, a similar scenario was observed with isolates TF2889 and 
TF36480, with +100 % kill of anaerobically incubated bacilli (Table 4.5.2).   
Similar activity was observed with OFL at day 2 (Table 4.5.1) with kill of the inoculum 
incubated under anaerobic conditions but not when incubated under aerobic circumstances. 
Ofloxacin at 0.25XMIC was not able to kill any on the bacilli under both aerobic and anaerobic 
conditions, while at the MIC concentration of this antibiotic only TF2889 was killed. This was 
on day 2 under anaerobic conditions. At 4XMIC, the potency of OFL showed signs of not being 
associated with either of the two conditions that were under investigation (Table 4.5.1). This was 
because on day 2, 3 out of the 5 isolates were killed by this drug under anaerobic conditions but 
under aerobic conditions kill was observed for these three isolates at day 7 while under anaerobic 
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conditions these isolates were still alive on that day (Table 4.5.2). Isolates TF2034 and TF36480 
were not killed at any drug concentration under both incubation conditions. 
KAN showed no major difference in its killing activity whether the bacilli were incubated 
aerobically or anaerobically at day 2 (Table 4.5.1). The only isolate where there was a difference 
was isolate TF2889, as at a concentration of 4XMIC of this antibiotic + 100% kill was observed 
with the anaerobically surviving bacilli but no kill was seen with aerobically incubated bacilli or 
at lower concentrations anaerobically. In contrast, isolate TF36480 was killed at the MIC 
concentration and at 4XMIC and this occurred under both conditions and at similar percentage 
kill. Isolates from the F28 family lineage (TF2889 and TF36480) were the only isolates that 
experienced kill at day 2 at the concentration of 4XMIC (Table 4.5.1). Only a small percentage 
of the initial population of isolate TF2889 escaped kill. TF36480 was susceptible under both 
conditions at this concentration, with +100% death under both aerobic and anaerobic conditions. 
By day 7 KAN (Table 4.5.2) showed better lethal activity towards aerobically incubated bacilli 
as at the concentration of 0.25XMIC, this antibiotic was able to kill almost 100% of TF2889 and 
MODS11 under aerobic conditions. This is the only time that there was any kill of the bacteria 
by this anti-TB drug at this concentration.  Again, at a concentration of the MIC there was killing 
of isolates MODS682, TF2889 and TF36480 while there was no kill of bacilli under 
anaerobiosis. With TF2889 and TF36480 at a concentration 4XMIC, the killing was experienced 
under both conditions with minor differences, while the MODS11 population was killed when it 
was grown aerobically, but survived under anaerobiosis. Isolate TF2034 was the only isolate that 
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4.6 Gene Expression 
 
Gene expression levels were measured to establish whether there was metabolic activity under 
both aerobic and anaerobic incubation and whether the gene expression was in keeping with the 
presence or absence of oxygen. All the three genes (menB, sdhA and fdxA) that were chosen for 
the study were expressed at different levels under the two conditions that the bacilli were 
harvested from. Isolate TF1538 (susceptible) had the highest expression levels for all three genes 
under aerobic conditions, while these genes were less expressed under anaerobic conditions. 
With the MDR isolate TF3203; the three genes were detected under aerobic conditions, while 
under anaerobic conditions there was no amplification of these genes even thou there was 
amplification of the endogenous control (16S rRNA) and the method that was used for the 
extraction of the RNA produced intact RNA (Figure 4.6.1). Gene expression levels of the XDR 
isolates (TF3228 and TF3229) were the lowest amongst the isolates tested in this study. The 
sdhA and menB genes were expressed at higher levels under anaerobic conditions for both 
isolates as compared to under aerobic conditions, with menB being expressed at a higher level 
under anaerobic conditions in isolate TF3229 (Figures 4.6.2 and 4.6.3).  The ferrodoxin gene 
(fdxA) was expressed at a highest level under anaerobic conditions in TF3229 (Figure 4.6.4). 
This was the only time in our experiments that this gene was upregulated under anaerobic 
conditions. 
Overall all three genes were better expressed under aerobic conditions. MenB was expressed 
more under aerobic conditions in H37Rv; isolates TF1538 and TF3203, while it was down-
regulated under anaerobic conditions. The other gene that is involved in energy metabolism in 
bacteria that was studied was succinate dehydrogenase (sdhA).  A similar trend is seen with this 





Figure 4.6.1: RNA samples run on a 2% agarose gel at 100V for an hour. Lane 1 – DNA 
molecular marker XIV (100 bp);  Lane 3 – H37Rv; Lane 4 – TF3229; Lane 5 – H37Rv; Lane 7 – 
TF1001; Lane 11 – TF 1538.   
 
Figure 4.6.1, shows the bands of the RNA that was extracted from the cultures of the isolates in 
an agarose gel. The 23S rRNA and the 16S rRNA bands are seen to correspond to the known 


















































































































Chapter 5: Discussion 
 
The low metabolic state, in which some cells of Mycobacterium tuberculosis are surviving when 
inside the host, is thought to be assumed by these bacilli when they encounter stressful 
environmental conditions that the hosts’ immune system utilizes to fight off any potential threats. 
In this low metabolic state these are referred to as persistent bacilli since they are tolerant to a 
number of stresses including the anaerobic conditions found in the host’s lesions that are not 
communicating with the bronchial tree (Wayne and Lin, 1982; Wayne and Hayes, 1996). A 
number of antimicrobial agents that are used for the treatment of tuberculosis (TB) are known to 
be more active against actively metabolizing, multiplying bacilli as compared to persistent 
bacteria (Parrish et al., 2009). This has been recognized as the possible explanation for the long 
duration of treatment as research has shown that M. tuberculosis found in sputum specimens are 
exposed to different levels of oxygen saturation and are morphologically different from the 
bacilli that are grown in the laboratory (Fattorini et al., 2013). This is summarized in table 5.1 
according to the different locations of the TB lesions in the lungs. 
Table 5.1: Replication rate of M. tuberculosis under various oxygen concentrations during 
infection inside the host 
Site in the host Oxygen concentration Replication Rate 
Alveoli Highly aerobic Rapid Replication 
Inflammation and Necrosis Microaerophilic Reduced Replication 
Blocked Lesions Minimal Oxygen No / Minimal Replication 
*Wayne and Lin, 1982; Zhang et al., 2012; Fattorini et al., 2013 
The differences in level of oxygen availability in these three different mycobacterial populations 
may mean that, they are also physiologically different, which includes the replication rate as well 
as their metabolic activity. Since antibacterial drugs act by interfering in essential metabolic 
pathways, such differences may also have an influence on the drug susceptibility of the bacilli if 
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the drug target is associated with characteristics of bacilli multiplying under specific conditions 
but not or less active under the other conditions.  
In our study, we aimed to expose clinical of isolates of M. tuberculosis with different drug 
susceptibility profiles (e.g. Susceptible, MDR and XDR), to various antimicrobial agents that are 
currently part of the TB treatment regimens. The isolates were cultured under different 
environmental conditions with an aim of comparing the level of drug susceptibility of bacilli that 
are in a similar metabolic state as the different populations of bacilli present in the different lung 
lesions. We attempted to obtain drug susceptibility profiles of these isolates by determining the 
minimum inhibitory concentrations (MICs) and compare the values obtained aerobically and 
anaerobically. 
M. tuberculosis is believed to replicate slower or replicate at a negligible rate under anaerobic 
conditions, low metabolic activities and reduced membrane transport processes (functions 
associated with ATP generation) are characteristic of M. tuberculosis growing under such 
conditions (Leistikow et al., 2010; Turapov et al., 2014). This was the reason the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was conducted on a few 
isolates aerobically and not conducted under anaerobiosis. We believed that since the bacilli 
would have already be metabolising anaerobically by the time we planned to perform the 
susceptibility testing (which was also to be done under anaerobiosis), the bacilli would not have 
produced sufficient ATP to help in converting the MTT substrate into formazan. On a study done 
by Vistica et al., 1991, they found that cells that are on different phases of growth reduced the 
MTT differently. As the cells aged, their ability to reduce MTT decreased. They postulated that 
this was because as the cells age, they produce less NADH / NADPH which is needed in order to 
reduce the MTT into formazan, therefore there is less of these nucleotides to help in reducing 
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MTT. Doing an MTT assay under anaerobic conditions would have led to false results in the 
form of increased MICs under such conditions. Therefore, MICs were performed using the 
methodology described for the Microscopic Observation Drug Susceptibility (MODS) assay 
(Caviedes et al., 2000) as with this test no indicator needs to be modified for the identification of 
the MIC and agar based methods would not have worked as previous studies have revealed that 
M. tuberculosis growing under anaerobiosis may lack the ability of forming colonies on agar 
(Anuchin et al., 2009). Once again using this method would have led to false increase of MICs 
under anaerobic conditions due to underestimating the number of viable bacilli. These concerns 
were proven to be valid since no growth was obtained in the drug free growth controls under 
anaerobic circumstances. 
MICs under aerobic incubation 
Under aerobic conditions, H37Rv had MICs that were greater than the MICs of some of the 
susceptible isolates. This was the case with both the antimicrobial susceptibility tests (MTT and 
MODS assays) that were used in this study. Some of these MICs indicated that this strain that 
was supposed to be fully susceptible was resistant to some of the antimicrobial agents, namely 
ethambutol (EMB), kanamycin (KAN) and capreomycin (CAP). Resistance of H37Rv to EMB 
was indicated by both methods that were employed for MIC determination, i.e. MTT and MODS 
assays, while resistance to KAN and CAP was indicated by the MODS assay only. This 
reference strain was resistant with an MIC of 16 mg/L to EMB according to the MODS assay, 
while it had an MIC of 4 mg/L when the MTT assay was employed. 4 mg/L for EMB is 
susceptible according to the MGIT960 critical concentration while it is resistant according to the 
BACTEC460 critical concentration. Resistance of this reference strain was unexpected as H37Rv 
is supposed to be fully susceptible. This observation may be explained by the fact that some 
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bacilli may have undergone genetic modification in subsequent subcultures (Lakshmi et al., 
2012). In a study done by Ioerger and colleagues (2010), it was found that H37Rv from 6 
different laboratories had distinct polymorphisms, which they attributed to the different ways 
these isolates were stored. These modifications may give rise to drug susceptibility changes. 
Again during the passaging of the bacilli, if a single colony that has a certain mutation (e.g. a 
mutation that confer drug susceptibility) is selected and propagated, it means that the culture that 
is later on stored and used from that colony will differ in drug susceptibility from the original 
culture. It is therefore imperative that the drug susceptibility of this reference strain be evaluated 
from time to time. The H37Rv strain is used in the Department of Microbiology and Infection 
Prevention at UKZN for over 10 years. During that time an undetermined number of subcultures 
have taken place. The discrepancies with the original obtained strain which was fully susceptible, 
may be based in just one mutation in the rrs gene that renders the organism resistant to both 
KAN and CAP (Alangaden et al., 1998; Bastian et al., 2001; Zhang and Yew, 2009; Kolyva and 
Karakousis, 2012). The findings with EMB may be based on the difference in methodologies. 
This drug is known to be problematic in susceptibility testing. 
Overall, the MICs for the susceptible isolates obtained with the MTT assay were either greater 
than or equal to those determined by the MODS assay. With the drug resistant isolates the 
reverse of this was true, with exceptions for two isolates, each for a different drug. Variations in 
the MICs obtained from different drug susceptibility methods are expected as these methods 
depend on different indicators for the identification of the MIC (Ängeby et al., 2012). This 
observation could be attributed to the fact that the MTT assay is dependent on generation of ATP 
which is associated with high replication rate. Bacilli that are non-replicating (dormant) produce 
lower levels of ATP as compared to the actively replicating bacilli (Leistikow et al., 2010). The 
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drug resistant isolates are believed to replicate slower compared to the susceptible isolates due to 
fitness cost which is caused by the drug resistance trait (Meacci et al., 2005). The MODS assay 
is based on the growth of the bacilli and the formation of the characteristic whorls of cording 
bacilli and not on any indicator that changes due to metabolic activity (Caviedes et al., 2000). 
Since drug resistant bacilli replicate slower (Meacci et al., 2005) which may mean that they 
produce less energy as energy generation is associated with the rate of replication (Leistikow et 
al., 2010), that may mean that the energy may be insufficient to cleave the indicator substrate 
resulting in colour change, the MICs in the MTT assay should be lower compared to the results 
from the MODS assay, as it would take more bacteria (drug resistant) than the susceptible 
bacteria to give sufficient energy to cleave the indicator molecule. With the MODS assay as soon 
as the typical bacterial growth is visible one can be able to identify the MIC (Caviedes et al., 
2000). Again the incubation period for the resistant isolates for the MTT assay was double that 
of the susceptible isolate as there was hardly any colour change when the incubation period was 
seven days as it was with the susceptible isolates. This further validates our observation about the 
dependency of the MTT assay on the rate of replication. Although the formation of the 
microscopically observed bacterial growth in the MODS is also dependent on replication rates, it 
is unlikely that this would lead to the same delay in observations between the two assays. 
The consequences of the differences in the replication rates were also seen in the level of 
expression of the genes as one susceptible isolate and the reference strain tested showed higher 
levels of expression of all three genes tested i.e. menB, sdhA and fdxA. Both these organisms 
replicated at a higher rate in the optimal and conducive aerobic environment which may be 
accompanied by high level of energy generation and usage of menaquinone and succinate 
dehydrogenase (products of menB and sdhA respectively). With both drug resistant isolates, the 
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expression of menB and sdhA was lower under aerobic conditions, which may indicate the 
slower growth rate under this condition compared to the growth rate of the susceptible 
organisms. Although these genes were down-regulated under anaerobic conditions in the 
susceptible organism and the MDR isolate and upregulated in the XDR isolates (with both menB 
and sdhA being upregulated in one isolate, the other isolate with only menB being upregulated), 
they were still expressed, indicating their essentiality for the survival of the bacilli overall. The 
products of these genes need to be synthesized as they are important for the maintaining 
membrane potential in the bacilli (Black et al., 2014).   
All the MDR and XDR isolates were resistant to both INH and RIF. This was in accordance with 
the definitions, as MDR isolates are characterized as being resistant to INH and RIF while XDR 
isolates are MDR isolates with resistance to a fluoroquinolones and an injectable agent (Ahmad, 
2011). The XDR isolates together with one classified as MDR, were resistant to ofloxacin 
(OFL). This potent second line drug is used in the treatment of infections with MDR isolates and 
is used as a criterion for defining and classifying a strain as an XDR strain (Malik et al., 2012). 
All the XDR isolates that were used in this study were from theF15/LAM4/KZN family while 
one OFL resistant MDR was from the F28 family. Such isolates are now known as pre-XDR.  
The XDR isolates were only susceptible to linezolid (LIN) out of all the 9 antimicrobial agents 
that were tested. This antimicrobial agent was the only drug tested in this study to which no 
resistance was found. This was expected as LIN is one of the newest drugs (Long and Vester, 
2012) and little drug resistance has been reported to this drug in general (Vardakas et al., 2009).    
Most of the isolates that were resistant to either KAN or CAP were also resistant to the other. 
Resistance to both these antibiotics is associated with mutations in the rrs gene which may 
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explain why resistance to one of the two drugs would mean resistance to the other (Alangaden et 
al., 1998; Bastian et al., 2001; Zhang and Yew, 2009; Kolyva and Karakousis, 2012). In a study 
done by Bastian et al., (2001) in Europe on MDR strains, they found that 69% of KAN resistant 
strains had an MIC that was greater than 20 mg/L. In our study similar results were found as 9 of 
the 13 (69%) drug resistant isolates had MICs that were equal to or greater than 32 mg/L. Eight 
of these9 (89%) isolates had an MIC that was greater than 1024 mg/L. 
 Only one isolate from the group of isolates classified as susceptible was resistant to CAP with 
an MIC of 8 mg/L. This was the only drug that this isolate was resistant to. Ten of the 13 (77%) 
resistant (both MDR and XDR) isolates showed resistance to STR, with two of these having an 
MIC of 2 mg/L, a value that is difficult to interpret since 2mg/L is the proposed critical 
concentration in tests applying the BACTEC460. This means borderline susceptible. However, 
the critical concentration according to MGIT960 is 1 mg/L which makes these two isolates 
resistant. Since there is no proposed critical concentration for tests in home-made Middlebrook 
7H9, we have labelled them susceptible. This percentage of 77% STR resistance among MDR 
isolates is slightly lower compared to the findings from studies done among inmates in prisons in 
the former USSR, where they reported that 97.1% of the MDR strains to be resistant to STR 
(Bastian et al., 2001). All the isolates that were resistant to STR showed resistance to either or 
both KAN and CAP. Resistance to all three these antimicrobial agents in these isolates could be 
because of a mutation in the rrs gene as such mutations are cited as the reason for resistance to 
all these structurally related drugs (Alangaden et al., 1998; Bastian et al., 2001; Zhang and Yew, 




MICs under anaerobic conditions 
Although our primary aim was to assess and compare the MICs performed under aerobic and 
anaerobic conditions, of selected M. tuberculosis isolates performed, we were unable to do this 
as obtaining MICs under anaerobic conditions was not successful. No growth was observed in 
the drug free growth controls when the 24-well tissue culture plates used in the MODS assay 
were incubated anaerobically. For the determination of the anaerobic MICs; representatives from 
the different genotype families were chosen; namely the F11, F28 and F15/LAM4/KZN families 
as well as some unique isolates (not clustering according to IS6110 fingerprinting) and H37Rv. 
No growth was seen with the cultures that were first grown under anaerobiosis (cultures that had 
been incubated through the standing culture method) and then subjected to MIC determination 
under anaerobic conditions and the cultures that were first grown aerobically and then subjected 
to MIC determination under anaerobic conditions.  
Although M. tuberculosis has been classified as a strict aerobe for centuries and in some 
literature this still remains the case, Wayne and Hayes in 1996, demonstrated that M. 
tuberculosis can grow under anaerobic conditions. The bacilli grew slowly as witnessed by the 
slow increase in turbidity and non – significant change in the colony forming units (cfu) counts 
and the Wayne and Hayes method has been a method that has been adapted by most scientists in 
culturing M. tuberculosis anaerobically. Recent studies confirm that M. tuberculosis does 
replicate under oxygen deprived conditions with as little as 1% (Voskuil et al., 2004) and 1.3% 
oxygen as long as the environment is supplemented with carbon dioxide (Vilchèze et al., 2011).  
We provided a similar environment (mixed gas consisting of 5% carbon dioxide; 85% nitrogen 
and 10% hydrogen) for the bacilli during the anaerobic incubation of the plates for the 
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determination of MICs and also extended the incubation period to 40 days, but there was no 
growth observed.  
Interestingly, following the 40 days of no growth under anaerobic conditions, these plates were 
incubated aerobically, resulting in visible growth within a week. This, together with growth on 
the agar plates (incubated aerobically with 5% CO2) that were inoculated at the same time with 
the same inoculum that was used to inoculate the MODS plate validated that there was viable 
bacilli in the inoculum and still had the ability to replicate. This was not surprising as M. 
tuberculosis is known that following its dormant state in the non-growth favouring hypoxic 
environment it resuscitates once it is introduced to an oxygen rich environment (Voskuil et al., 
2004; Kolyva and Karakonsis, 2012; Nickel et al., 2012). These observations also indicated that 
the lack of oxygen was the hindering factor in producing visible growth under anaerobic 
conditions as it is the only factor that was different between the two scenarios. The lack of 
visible growth under anaerobic conditions in the MODS assay with the isolates that we worked 
with could be because the incubation period was not sufficient to provide visible growth. 
Although the incubation period under anaerobic conditions was almost three times longer (40 
days) than the incubation period under aerobic conditions (14 days), it was still not sufficient to 
give visible growth. This can be attributed to the fact that, M. tuberculosis replicates slower 
under anaerobic conditions, to an extent that it is negligible compared to an already slow 
replication rate of this pathogen even under optimal environmental conditions that include high 
oxygen concentrations. Under normal optimal conditions M. tuberculosis takes 16 hours on 
average to replicate (Beste et al., 2009) which is extremely slow compared to most bacteria that 
divide in 20 to 30 minutes.  
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We believe that if the plates were incubated for a longer period in the anaerobic environment we 
may have been able to observe growth on the plates as the lack of visible growth on the plates is 
not due to the fact the bacilli is dead but it is due to the fact that the bacilli lowers its metabolic 
activity and may stop replicating (enter the stationary phase) as some studies have suggested 
(Anuchin et al., 2009). In a study done by Anuchin et al., 2009, they showed that the longer the 
bacilli was incubated under anaerobic conditions the lower the colony forming unit counts 
became. But when they conducted the Most Probable Number assay, the opposite was observed.  
Hence we believe that in our study if we had incubated the plates for longer than we did we may 
have been able to observe growth. As with some studies growth has been witnessed in the 
anaerobic environment, but this was due to an extended incubation period of 6 – 9 months 
(Zhang et al., 2012). M. tuberculosis can actually retain its viability, surviving under 
anaerobiosis for 12 years (Wayne and Lin, 1982). However in our study, incubation for 6 to 9 
months would have had its own problems as the tests could then not have been performed in the 
small volumes of broth used in the MODS test. The media started drying up after 40 days. And 
also that the duration of efficacy of the drugs in solution after prolonged exposure to a 
temperature of 37oC duration is questionable. 
During hypoxic respiration M. tuberculosis changes metabolically and morphologically. 
Morphological changes include the thickening of the cell wall (Zahrt, 2003; Hett and Rubin, 
2008), which has an influence on the accessibility of the drugs to the bacilli. The cell wall 
components are also important in regulating persistence of M. tuberculosis (Wang et al., 2011). 
One of the metabolic changes that occur during hypoxic respiration is the upregulation of certain 
genes such as the genes that are part of the DosR regulon. In our study we utilized fdxA which is 
part of this regulon. Although this gene was expressed under both aerobic and anaerobic 
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conditions there was increased expression under the latter conditions in some of the drug 
resistant isolates. The expression of the genes from the DosR regulon is vital in ensuring survival 
of the bacilli under the ‘lethal’ anaerobic conditions (Fang et al., 2012). 
Killing experiments 
The time-kill experiments were conducted to see whether oxygen deprivation made organisms 
less or more susceptible to antibiotics. We choose to use MDR isolates for this since these 
isolates could potentially show an increase in susceptibility to INH and RIF because of their 
known resistance under aerobic conditions. Likewise, the same isolates, being susceptible under 
aerobic conditions to KAN and OFL, could show an increased tolerance to these drugs under 
oxygen deprivation.  
The effect of anaerobiosis of M. tuberculosis on susceptibility to INH and RIF differed. With 
INH, there was no effect of anaerobiosis as there was no kill of the isolates under anaerobic 
conditions. As expected, there was also lack of killing under aerobic conditions. The minimal 
bactericidal activity shown by INH under anaerobic conditions was in agreement with what other 
studies have found in terms of its decreased potency towards non-replicating bacilli as its targets 
are mainly the metabolic pathways that are active during replication (Parrish et al., 2009). M. 
tuberculosis under anaerobic conditions is known to replicate at a slower rate or to be non-
replicating. This would mean that processes such as mycolic acid synthesis which is the target 
for INH are not less available for anti-TB drug to act on under anaerobic conditions. Since INH 
would have fewer sites to act on, it will not be able to kill a lot of bacilli, hence less bactericidal 
activity towards M. tuberculosis growing anaerobically.  
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With RIF which is a protein synthesis inhibitor that binds to the DNA-dependant RNA 
polymerase during transcription of DNA to RNA (Wayne and Hayes, 1996), the opposite was 
observed. Bacilli growing under anaerobic conditions showed increased susceptibility when 
compared to the bacilli growing aerobically. This antimicrobial agent has been said to have 
better activity against non-replicating bacilli (Deb et al., 2009; Joshi, 2011) and has 
demonstrated some bactericidal activity in environments with minimal oxygen (Wayne and 
Hayes, 1996). In this study similar activity was observed. The possible reason for the better 
killing shown by this antibiotic under anaerobic conditions is that there is less gene transcription, 
resulting in decreased amounts of the drug target e.g. RNA polymerase available under such 
conditions. This decreased transcription under anaerobic conditions is due to the fact that under 
oxygen deprived conditions there is only 2% of protein synthesis that is occurring (Filippini et 
al., 2010) and that synthesis of DNA is terminated (Wayne and Hayes, 1996), resulting in 
decreased transcription. This means there is less target sites for RIF to act on. As a result fewer 
RIF molecules are needed to stop transcription hence it is more potent against non-replicating 
bacilli.  
With OFL and KAN, the effect of oxygen deprivation on the killing potency differed. By day 2 
susceptibility to OFL under anaerobic conditions increased, but by day 7 it decreased. This could 
be because at day 2, the percentage of cells that went into dormancy was lower than at day 7. 
OFL as a DNA synthesis inhibitor, will still have an impact (able to kill) on the anaerobic 
incubated bacilli as they will still be replicating at this stage. The level of dormancy increases, 
with longer incubation. Hence, the bacilli become more tolerant to OFL (Deb et al., 2009) the 
less active the bacilli are, the less DNA synthesis activity is happening and therefore decreased 
number of target sites for the drug to act on. With KAN the opposite was seen. By day 2 there 
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was no change in the susceptibility of the bacilli incubated under anaerobic conditions. But by 
day 7 there was a decrease in the susceptibility of M. tuberculosis. This is to be expected since 
the transport over the cell wall of aminoglycosides is mainly by proton motive force, a process 
that requires aerobic metabolism. This class of drugs can also enter the bacterial cell by diffusion 
but that process is much slower and is affected by the thickness of the cell wall. Changes in the 
cell wall permeability are highly associated with non-replicating bacilli as the cell wall becomes 
thicker under anaerobic conditions (Zahrt, 2003). If the cell wall is thicker, this will have an 
influence in the uptake of the drug into the inside of the bacilli.  
It should also be noted that KAN is a protein synthesis inhibitor (Mitchison and Davies, 2007) 
which binds to the 30S subunit resulting in the inhibition of translation (Kolyva and Karakousis, 
2012). Since there is less protein synthesis during anaerobiosis as witnessed in a study done by 
Filippini et al. (2010) where there was only about 2 % of protein synthesis occurring on 50 day 
old microaerophilic bacilli, then this drug would have less sites to act on.  
The anaerobically incubated bacilli were more susceptible to the drugs by day 2 compared to by 
day 7. This was witnessed with RIF, OFL and KAN. This could be because may be the 
concentration of the drug does not remain constant throughout the incubation period; it may be 
inactivated during that period.  Therefore, the efficacy of the drugs dissolved in the media and 
incubated at 37ºC is unknown and questionable. If this is the case, it will mean that the lack of 
killing that is seen by day 7 with some drugs while there was killing by the second day may be 
because the drugs concentrations may have reduced to sub-lethal concentration. And this 
concentration may not be equivalent to the concentration at day 2. If this is true, then that would 
mean that it is not because increased tolerance but decreased drug concentration during the 
incubation period.  
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RIF killed more effectively under anaerobic conditions. Its potency appeared to be time 
dependant as by day 2 under anaerobic conditions there was killing at lower concentrations while 
on day 7 kill only occurred at the highest concentration tested. Since the kill at the lower 
concentrations on day 2 was not 100%, the persisters that were not killed seem to have grown 
again by day 7.As RIF is a concentration dependant drug (Jayaram et al., 2003), this may mean 
that this drug’s potency decreases as incubation continues. OFL displayed the same phenomenon 
where susceptibility to this antibiotic under anaerobic conditions increased by day 2 but by day 
7, it had decreased. 
Another possibility is that as the bacilli spend more time under anaerobic conditions, the more 
their metabolism adapts to being anaerobic hence possessing more anaerobic characteristics. This 
may mean that the antibiotics will have fewer sites to act on. Bacilli that are surviving under 
anaerobiosis are said to be tolerant to a number of anti-TB drugs as these target actively growing 
bacilli (Parrish et al., 2009). The longer the bacilli are surviving anaerobically, the more they 
become dormant, hence the more they become tolerant to the drugs, i.e. the higher the drug 
concentration that would be able to kill such bacilli. This likely results from low replication rate 
or absence of replication of the bacilli under anaerobic conditions which results in tolerance to 
some antibiotics (Gomez et al., 2004). This characteristic is phenotypic and is inheritable 
(Fattorini et al., 2013). In 2004, Gomez et al., postulated that the persistent state assisted drug 
sensitive M. tuberculosis to be resistant or, better tolerant to some drugs (Daniel et al., 2011), 
and in another study done by Deb et al., (2009) they observed that the longer M. tuberculosis 
was grown under stressful conditions the more it became drug tolerant.  In this study the 
decrease in the potency of the drugs was only seen under anaerobic conditions, whereas under 
aerobic conditions the opposite was witnessed. This reason seems more valid than the former 
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reason (decrease in the potency over time) as under aerobic conditions the killings were greater 
by day 7. This was the case with RIF, OFL and KAN.   
 There were differences in the drug susceptibilities under anaerobic conditions amongst the 
isolates that were used for the killing experiments. We hypothesise that since these isolates are 
from different genetic backgrounds they may adapt to anaerobiosis at different rates; hence this 
will have an influence in their level of drug tolerance.   
There is still a lot of research that needs to be done as the MICs under anaerobic conditions are 
still unattainable. This makes it hard to evaluate the susceptibility of non-replicating M. 
tuberculosis. Although we were not able to determine the MIC under such conditions we were 
able to subculture the bacilli that had been exposed to drugs. Although the method used in the 
time-kill experiment was a more labour intensive and time consuming with a longer turnaround 
time, we were able to get an insight on the vulnerability of the bacilli towards the drugs. It 
indicates that bacilli from different genetic lineages take different duration to adapt to oxygen 
depletion, which may influence the bacilli’s drug tolerance.  
These results highlight the need for more drugs that are active against both aerobically and 
anaerobically metabolising M. tuberculosis as there was no drug from those tested in the time-
kill experiments that showed similar activity against both bacterial sub-populations. There is still 
a lot that is unknown about this bacilli’s anaerobic persistence, which seems to be a major 
contributor to its success as a pathogen. Hence, this study needs to be done more extensively, in 
the form of quantitative time-kill experiments as this will give more insight in the changes of the 
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A.1.1 Middlebrook 7H9 Broth for isolation of the single colonies 
4.7g Middlebrook 7H9 powder 
2ml glycerol 
0.5ml Tween 80 
900ml distilled water 
The above materials were mixed and autoclaved at 121ºC for 15 minutes 
100ml OADC was added once the media was cool. 
 
A.1.2 Middlebrook 7H9 Broth 
4.7g Middlebrook 7H9 powder 
2ml glycerol 
900ml distilled water 
The above materials were mixed and autoclaved at 121ºC for 15 minutes 
100ml OADC was added once the media was cool. 
 
A.1.3 Middlebrook 7H9 Broth MODS Assay  
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5.9g Middlebrook 7H9 powder 
3.1ml glycerol 
1.25g casitone 
900ml distilled water 
The above materials were mixed and autoclaved at 121ºC for 15 minutes 
OADC was added on the day of the assay at a quantity of 10%. 
 
A.1.4 Middlebrook 7H11 Agar 
21g Middlebrook 7H11 powder 
5g L-Asparagine monohydrate  
1g casitone 
5ml glycerol 
900ml distilled water 
The above materials were mixed and autoclaved at 121ºC for 15 minutes 
100ml OADC was added once the media was cool. 
For the selective media the antibiotics mentioned below were added at this point as well.  
Antibiotics for selective media:  
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200.000 units/L of Polymixin B  
 20 mg/L of Amphotericin B  
100 mg/L of Carbenicilin 
 20 mg/L of Trimethoprim  
 
A.1.5 Storage Media 
2g Proteose peptone 
16ml glycerol 
Make up to 200ml with distilled water 




B.1: MTT Assay reagents 
B.1.1: 20% Sodium Dodecyl Sulphate  





B.1.2: 50% Dimethylformamide 
25ml Dimethylformamide 
25ml distilled water 
The two reagents were mixed.  
 
B.1.3: MTT Solution  




C.1: Gel Electrophoresis 
C.1.1: 2% Agarose gel 
4g agarose  
200ml 1XTris-acetate-EDTA (TAE) Buffer 
C.1.2: 1XTris-acetate-EDTA (TAE) Buffer 
20ml 50X TAE Buffer 
980ml distilled water 
 
